


**CUMULATIVE
SUPPLEMENT 06
June 2009**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2009

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

Cumulative Supplement 6

June 2009

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Availability of the Edition	vi
1.5 Report of Counts for the Prescription Drug Product List	vi
1.6 Cumulative Supplement Legend	vii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

29th EDITION

**CUMULATIVE SUPPLEMENT 6
June 2009**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 28th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 29th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 30th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@cderr.fda.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ABLE LABORATORIES INC (ABLE)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARM)
AXIOM PHARMACEUTICAL CORP (AXIOM PHARM)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARM)
DABUR ONCOLOGY PLC (DABUR ONCOLOGY PLC)	FRESENIUS KABI ONCOLOGY PLC (FRESENIUS KABI ONCOL)
HALSEY DRUG CO INC (HALSEY)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARM)
IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS (IVAX PAHRMS)	IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX SUB TEVA PHARM)

NORTON WATERFORD LTD
(NORTON WATERFORD)

IVAX PHARMACEUTICALS INC SUB TEVA
PHARMACEUTICALS USA
(IVAX SUB TEVA PHARM)

TORPHARM INC
(TORPHARM)

APOTEX INC
(APOTEX)

ZENITH GOLDLINE
(ZENTH GOLDLINE)

IVAX PHARMACEUTICALS INC SUB TEVA
PHARMACEUTICALS USA
(IVAX SUB TEVA PHARM)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Annual Edition. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.exe and eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly. Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts

are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2008</u>	<u>MAR 2009</u>	<u>JUN 2009</u>	<u>SEPT 2009</u>
DRUG PRODUCTS LISTED	12751	12910	13027	
SINGLE SOURCE	2433 (19.1%)	2449 (19.0%)	2451 (18.8%)	
MULTISOURCE	10229 (80.2%)	10372 (80.3%)	10487 (80.5%)	
THERAPEUTICALLY EQUIVALENT	10072 (79.0%)	10216 (79.1%)	10333 (79.3%)	
NOT THERAPEUTICALLY EQUIVALENT	157 (1.2%)	156 (1.2%)	154 (1.2%)	
EXCEPTIONS ¹	89 (0.7%)	89 (0.7%)	89 (0.7%)	
NEW MOLECULAR ENTITIES APPROVED	15	5	6	
NUMBER OF APPLICANTS	719	724	732	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 28TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

1-1

ACARBOSE

TABLET; ORAL

ACARBOSE

AB	IMPAX LABS	25MG	N78441 001	May 14, 2009	May	NEWA
AB		50MG	N78441 002	May 14, 2009	May	NEWA
AB		100MG	N78441 003	May 14, 2009	May	NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ SANDOZ 300MG;30MG

N81250 001 Jul 16, 1992 Mar DISC

@ 300MG;60MG

N81249 001 Jul 16, 1992 Mar DISC

TYLENOL W/ CODEINE NO. 4

AA	ORTHO MCNEIL JANSSEN	300MG;60MG	N85055 004		Mar	CMFD
----	----------------------	------------	------------	--	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MALLINCKRODT 500MG;5MG

N89006 001 Aug 09, 1985 Feb CTNA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

PERCOCET

AA	+ ENDO PHARMS	325MG;2.5MG	N40330 001	Jun 25, 1999	May	CTEC
----	---------------	-------------	------------	--------------	-----	------

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

@ SANDOZ 650MG;65MG

N89959 001 Jul 18, 1989 Mar DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

@ SANDOZ 650MG;100MG

N70443 001 Jan 23, 1986 Mar DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	MYLAN	325MG;37.5MG	N77858 001	Sep 26, 2008	Apr	CAHN
----	-------	--------------	------------	--------------	-----	------

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

@ HOSPIRA EQ 500MG BASE/VIAL

N40108 001 Oct 30, 1995 Apr DISC

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

>D>	@ APOTHECON	200MG	N74889 001	Oct 31, 1997	Jun	CAHN
-----	-------------	-------	------------	--------------	-----	------

>A>	@ BELCHER PHARMS	200MG	N74889 001	Oct 31, 1997	Jun	CAHN
-----	------------------	-------	------------	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

>D>	@ APOTHECON	400MG	N74891 001	Oct 31, 1997	Jun	CAHN
-----	-------------	-------	------------	--------------	-----	------

TABLET; ORAL

	ACYCLOVIR							
>D>	@ APOTHECON	800MG	N74891	002	Oct 31, 1997	Jun	CAHN	
>A>	@ BELCHER PHARMS	400MG	N74891	001	Oct 31, 1997	Jun	CAHN	
>A>	@	800MG	N74891	002	Oct 31, 1997	Jun	CAHN	

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

	@ HOSPIRA	EQ 500MG BASE/VIAL	N74758	001	Apr 22, 1997	Apr	DISC	
	@	EQ 1GM BASE/VIAL	N74758	002	Apr 22, 1997	Apr	DISC	

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

AP	LUITPOLD	3MG/ML	N90010	001	Apr 28, 2009	Apr	NEWA	
AP	STRIDES ARCOLAB LTD	3MG/ML	N78686	001	May 13, 2009	May	NEWA	
>A>	AP	WOCKHARDT	N90220	001	Jul 20, 2009	Jun	NEWA	

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

	@ ARMSTRONG PHARMS	0.09MG/INH	N72273	001	Aug 14, 1996	Jan	DISC	
--	--------------------	------------	--------	-----	--------------	-----	------	--

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

	@ BAUSCH AND LOMB	EQ 0.083% BASE	N75358	001	Mar 29, 2000	Apr	DISC	
AN	HOLOPACK INTL	EQ 0.083% BASE	N77839	001	Dec 16, 2008	Jan	CAHN	
AN	TEVA PARENTERAL	EQ 0.083% BASE	N75343	001	Nov 09, 1999	Apr	CAHN	

TABLET; ORAL

ALBUTEROL SULFATE

	@ SANDOZ	EQ 2MG BASE	N72151	001	Dec 05, 1989	Mar	DISC	
	@	EQ 4MG BASE	N72152	001	Dec 05, 1989	Mar	DISC	

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN	TEVA PARENTERAL	EQ 0.083% BASE;0.017%	N76724	001	Dec 31, 2007	Apr	CAHN	
----	-----------------	-----------------------	--------	-----	--------------	-----	------	--

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

>A>	AB	GLENMARK GENERICS	0.05%	N79061	001	Jun 23, 2009	Jun	NEWA
-----	----	-------------------	-------	--------	-----	--------------	-----	------

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB	SANDOZ	EQ 5MG BASE	N75871	001	Apr 22, 2009	Apr	NEWA	
AB		EQ 10MG BASE	N75871	002	Apr 22, 2009	Apr	NEWA	
AB		EQ 35MG BASE	N75871	004	Apr 22, 2009	Apr	NEWA	
AB		EQ 40MG BASE	N75871	003	Apr 22, 2009	Apr	NEWA	
AB		EQ 70MG BASE	N75871	005	Apr 22, 2009	Apr	NEWA	

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

@ SANDOZ	100MG	N70268 001	Dec 31, 1985	Mar	DISC
@	300MG	N70269 001	Dec 31, 1985	Mar	DISC

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB +	PAR PHARM	5MG	N70346 001	Jan 22, 1986	Jan	CTEC
AB	SIGMAPHARM LABS LLC	5MG	N79133 001	Jan 30, 2009	Jan	NEWA
AB	MIDAMOR					
AB	PADDOCK LABS	5MG	N18200 001		May	CMFD

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ SANDOZ	EQ 5MG ANHYDROUS; 50MG	N73357 001	Nov 27, 1991	Mar	DISC
----------	------------------------	------------	--------------	-----	------

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

@ HOSPIRA	250MG/ML	N70888 001	Jun 16, 1988	Apr	DISC
-----------	----------	------------	--------------	-----	------

TABLET; ORAL

AMICAR

XANODYNE PHARM	1GM	N15197 002	Jun 24, 2004	Jan	NEWA
----------------	-----	------------	--------------	-----	------

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

>D>	AP	HOSPIRA	25MG/ML	N87242 001	Oct 26, 1983	Jun	CRLD
>A>	AP	+	25MG/ML	N87242 001	Oct 26, 1983	Jun	CRLD
		AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%					
		@ HOSPIRA	100MG/100ML	N88147 002	May 03, 1983	Apr	DISC
		@	200MG/100ML	N88147 003	May 03, 1983	Apr	DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

>D>	AP	+	INTL MEDICATION SYS	50MG/ML	N21594 001	Feb 04, 2004	Jun	DISC
>A>		@		50MG/ML	N21594 001	Feb 04, 2004	Jun	DISC

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	MYLAN	200MG	N75188 001	Feb 24, 1999	Apr	CAHN
----	-------	-------	------------	--------------	-----	------

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	ALKEM	EQ 2.5MG BASE	N78925 001	May 04, 2009	Apr	NEWA	
AB		EQ 5MG BASE	N78925 002	May 04, 2009	Apr	NEWA	
AB		EQ 10MG BASE	N78925 003	May 04, 2009	Apr	NEWA	
AB	GLENMARK GENERICS	EQ 2.5MG BASE	N78552 001	Apr 08, 2009	Mar	NEWA	
AB		EQ 5MG BASE	N78552 002	Apr 08, 2009	Mar	NEWA	
AB		EQ 10MG BASE	N78552 003	Apr 08, 2009	Mar	NEWA	
>A>	AB	ORCHID HLTHCARE	EQ 2.5MG BASE	N78453 001	Jul 02, 2009	Jun	NEWA

TABLET; ORAL

AMLODIPINE BESYLATE

>A>	AB	ORCHID HLTHCARE	EQ 5MG BASE	N78453 002	Jul 02, 2009	Jun	NEWA
>A>	AB		EQ 10MG BASE	N78453 003	Jul 02, 2009	Jun	NEWA
	AB	SYNTHON PHARMS	EQ 2.5MG BASE	N77080 001	Jun 27, 2007	Jan	CAHN
	AB		EQ 5MG BASE	N77080 002	Jun 27, 2007	Jan	CAHN
	AB		EQ 10MG BASE	N77080 003	Jun 27, 2007	Jan	CAHN

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

EXFORGE HCT

NOVARTIS

			5MG;12.5MG;160MG	N22314 001	Apr 30, 2009	Apr	NEWA
			5MG;25MG;160MG	N22314 002	Apr 30, 2009	Apr	NEWA
			10MG;12.5MG;160MG	N22314 003	Apr 30, 2009	Apr	NEWA
			10MG;25MG;160MG	N22314 004	Apr 30, 2009	Apr	NEWA
	+		10MG;25MG;320MG	N22314 005	Apr 30, 2009	Apr	NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	AB	APOTEX	250MG;EQ 125MG BASE	N65333 001	Feb 24, 2009	Feb	NEWA
	AB		500MG;EQ 125MG BASE	N65333 002	Feb 24, 2009	Feb	NEWA

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLONIDINE HYDROCHLORIDE

	AT	AKORN INC	EQ 0.5% BASE	N77764 001	Mar 12, 2009	Feb	NEWA
	AT	+ ALCON	EQ 0.5% BASE	N20258 001	Jul 30, 1993	Feb	CFTG

ARMODAFINIL

TABLET; ORAL

NUVIGIL

CEPHALON

			100MG	N21875 002	Mar 26, 2009	Mar	CMFD
			200MG	N21875 005	Mar 26, 2009	Mar	NEWA

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

NOVARTIS

			20MG;120MG	N22268 001	Apr 07, 2009	Apr	NEWA
--	--	--	------------	------------	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@ SANDOZ

			325MG;50MG;40MG	N86398 002	Apr 06, 1984	Mar	DISC
--	--	--	-----------------	------------	--------------	-----	------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

@ SOLCO HLTHCARE

ORPHENGESIC FORTE

@ SOLCO HLTHCARE

			385MG;30MG;25MG	N75141 001	May 29, 1998	Jan	CAHN
			770MG;60MG;50MG	N75141 002	May 29, 1998	Jan	CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

>A>	AB	IPCA LABS LTD	25MG	N77877 001	Dec 27, 2006	Jun	CAHN
>A>	AB		50MG	N77877 002	Dec 27, 2006	Jun	CAHN
>A>	AB		100MG	N77877 003	Dec 27, 2006	Jun	CAHN
>D>	AB	OHM LABS	25MG	N77877 001	Dec 27, 2006	Jun	CAHN
>D>	AB		50MG	N77877 002	Dec 27, 2006	Jun	CAHN
>D>	AB		100MG	N77877 003	Dec 27, 2006	Jun	CAHN

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

@ HOSPIRA

10MG/ML

N74740 001 Mar 28, 1997 Jan DISC

ATRACURIUM BESYLATE PRESERVATIVE FREE

@ HOSPIRA

10MG/ML

N74741 001 Mar 28, 1997 Jan DISC

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

>D>		@ VALEANT	0.025MG;1MG	N17744 002		Jun	CMFD
>A>	+		0.025MG;1MG	N17744 002		Jun	CMFD

AZACITIDINE

INJECTABLE; IV-SC

VIDAZA

+ CELGENE

100MG/VIAL

N50794 001 May 19, 2004 Mar CAHN

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

@ APOTEX INC

EQ 0.125MG BASE/SPRAY

N77954 001 Apr 30, 2009 Apr DISC

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

>A>	AP	HOSPIRA	EQ 500MG BASE/VIAL	N65500 001	Jun 26, 2009	Jun	NEWA
>A>	AP		EQ 500MG BASE/VIAL	N65511 001	Jun 26, 2009	Jun	NEWA
	AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	N65506 001	Mar 24, 2009	Mar	NEWA

BACLOFEN

TABLET; ORAL

BACLOFEN

	AB	MYLAN	10MG	N77181 001	Jul 29, 2005	Apr	CAHN
	AB		20MG	N77121 002	Jul 29, 2005	Apr	CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

TREANDA

+ CEPHALON

25MG/VIAL

N22249 002 May 01, 2009 May NEWA

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

COGENTIN

+ LUNDBECK INC

1MG/ML

N12015 001 Apr CAHN

BENZYL ALCOHOL

LOTION; TOPICAL

BENZYL ALCOHOL

+ SCIELE PHARMA INC 5% N22129 001 Apr 09, 2009 Apr NEWA

ULESFIA

+ SCIELE PHARMA INC 5% N22129 001 Apr 09, 2009 May CTNA

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BESIVANCE

+ BAUSCH AND LOMB EQ 0.6% BASE N22308 001 May 28, 2009 May NEWA

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

TACLONEX

+ LEO PHARM 0.064%;0.005% N21852 001 Jan 09, 2006 Mar CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

LUXIQ

+ CONNECTICS EQ 0.12% BASE N20934 001 Feb 28, 1999 May CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA SUN PHARM INDS INC 5MG N40897 001 Apr 22, 2009 Apr NEWA

AA 10MG N40897 002 Apr 22, 2009 Apr NEWA

AA 25MG N40897 003 Apr 22, 2009 Apr NEWA

AA 50MG N40897 004 Apr 22, 2009 Apr NEWA

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

>A> ACCORD HLTHCARE INC 50MG N78917 001 Jul 06, 2009 Jun NEWA

>A> AB KUDCO IRELAND 50MG N77995 001 Jul 06, 2009 Jun NEWA

>A> AB MYLAN 50MG N79185 001 Jul 06, 2009 Jun NEWA

>A> AB SANDOZ 50MG N78575 001 Jul 06, 2009 Jun NEWA

>A> AB SUN PHARMA GLOBAL 50MG N79110 001 Jul 06, 2009 Jun NEWA

>A> AB SYNTHON PHARMS 50MG N77973 001 Jul 06, 2009 Jun NEWA

>A> AB TEVA 50MG N76932 001 Jul 06, 2009 Jun NEWA

>A> AB ZYDUS PHARMS USA INC 50MG N79089 001 Jul 06, 2009 Jun NEWA

CASODEX

>D> + ASTRAZENECA 50MG N20498 001 Oct 04, 1995 Jun CFTG

>A> AB + 50MG N20498 001 Oct 04, 1995 Jun CFTG

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AT TEVA PARENTERAL 0.2% N76372 001 Sep 10, 2004 Apr CAHN

BROMOCRIPTINE MESYLATE

TABLET; ORAL

CYCLOSET

+ VEROSCIENCE EQ 0.8MG BASE N20866 001 May 05, 2009 May NEWA

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

>A>		BROMFED-DM							
>A>	+	MORTON GROVE	2MG/5ML;10MG/5ML;30MG/5ML	N88811	001	Jun 07, 1985	Jun	CTNA	
>D>	AA	WOCKHARDT EU	2MG/5ML;10MG/5ML;30MG/5ML	N89681	001	Dec 22, 1988	Jun	DISC	
>A>		@	2MG/5ML;10MG/5ML;30MG/5ML	N89681	001	Dec 22, 1988	Jun	DISC	
	AA		2MG/5ML;10MG/5ML;30MG/5ML	N89681	001	Dec 22, 1988	Apr	CAHN	
>D>		MYPHETANE DX							
>D>	AA	+ MORTON GROVE	2MG/5ML;10MG/5ML;30MG/5ML	N88811	001	Jun 07, 1985	Jun	CTNA	

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

AN		APOTEX	0.25MG/2ML	N78202	001	Mar 30, 2009	Mar	NEWA	
AN			0.5MG/2ML	N78202	002	Mar 30, 2009	Mar	NEWA	
AN		TEVA PARENTERAL	0.25MG/2ML	N77519	001	Nov 18, 2008	Apr	CAHN	
AN			0.5MG/2ML	N77519	002	Nov 18, 2008	Apr	CAHN	

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SENSORCAINE

>D>	AP	ABRAXIS BIOSCIENCE	0.25%	N70552	001	May 21, 1986	Jun	CAHN	
>D>	AP		0.5%	N70553	001	May 21, 1986	Jun	CAHN	
>D>	AP		0.75%	N70554	001	May 21, 1986	Jun	CAHN	
>A>	AP	APP PHARMS	0.25%	N70552	001	May 21, 1986	Jun	CAHN	
>A>	AP		0.5%	N70553	001	May 21, 1986	Jun	CAHN	
>A>	AP		0.75%	N70554	001	May 21, 1986	Jun	CAHN	

INJECTABLE; SPINAL

SENSORCAINE

>D>	AP	ABRAXIS BIOSCIENCE	0.75%	N71202	001	Apr 15, 1987	Jun	CAHN	
>A>	AP	APP PHARMS	0.75%	N71202	001	Apr 15, 1987	Jun	CAHN	

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SENSORCAINE

>D>	AP	ABRAXIS BIOSCIENCE	0.25%;0.0091MG/ML	N70966	001	Oct 13, 1987	Jun	CAHN	
>D>	AP		0.25%;0.0091MG/ML	N70967	001	Oct 13, 1987	Jun	CAHN	
>D>	AP		0.5%;0.0091MG/ML	N70968	001	Oct 13, 1987	Jun	CAHN	
>A>	AP	APP PHARMS	0.25%;0.0091MG/ML	N70966	001	Oct 13, 1987	Jun	CAHN	
>A>	AP		0.25%;0.0091MG/ML	N70967	001	Oct 13, 1987	Jun	CAHN	
>A>	AP		0.5%;0.0091MG/ML	N70968	001	Oct 13, 1987	Jun	CAHN	

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1		WATSON LABS	100MG	N79095	001	Mar 24, 2009	Mar	NEWA	
AB2			150MG	N79094	001	Mar 24, 2009	Mar	NEWA	
AB1			150MG	N79095	002	Mar 24, 2009	Mar	NEWA	
AB1			200MG	N79095	003	Mar 24, 2009	Mar	NEWA	

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

AB	+	BRISTOL MYERS SQUIBB	15MG	N18731	003	Apr 22, 1996	Feb	CRLD	
		@	30MG	N18731	004	Apr 22, 1996	Feb	DISC	

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	5MG	N78246 001	Feb 27, 2009	Feb	NEWA
AB		10MG	N78246 002	Feb 27, 2009	Feb	NEWA
AB		15MG	N78246 003	Feb 27, 2009	Feb	NEWA
AB		30MG	N78246 004	Feb 27, 2009	Feb	NEWA
AB	MYLAN	5MG	N75467 001	Feb 28, 2002	Apr	CAHN
AB		7.5MG	N75467 002	Mar 28, 2001	Apr	CAHN
AB		10MG	N75467 003	Feb 28, 2002	Apr	CAHN
AB		15MG	N75467 004	Feb 28, 2002	Apr	CAHN
	@ SANDOZ	5MG	N75413 001	Mar 19, 2002	Mar	DISC
	@	10MG	N75413 002	Mar 19, 2002	Mar	DISC
	@	15MG	N75413 003	Mar 19, 2002	Mar	DISC

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP	HIKMA FARMACEUTICA	1MG/ML	N78400 001	May 01, 2009	Apr	NEWA
AP		2MG/ML	N78247 001	Apr 29, 2009	Apr	NEWA
AP		2MG/ML	N78400 002	May 01, 2009	Apr	NEWA

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFFEINE CITRATE

AP	PADDOCK LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N77233 001	Sep 21, 2006	Apr	CAHN
----	--------------	------------------------------------	------------	--------------	-----	------

CALCITONIN, SALMON

SPRAY, METERED; NASAL

CALCITONIN-SALMON

AB	MDRNA	200 IU/SPRAY	N76979 001	Jun 08, 2009	May	NEWA
----	-------	--------------	------------	--------------	-----	------

CALCITRIOL

CAPSULE; ORAL

ROCALTROL

AB	VALIDUS PHARMS	0.25UGM	N18044 001		Mar	CAHN
AB	+	0.5UGM	N18044 002		Mar	CAHN

OINTMENT; TOPICAL

VECTICAL

	+	GALDERMA LABS LP	3UGM/GM	N22087 001	Jan 23, 2009	Jan	NEWA
--	---	------------------	---------	------------	--------------	-----	------

SOLUTION; ORAL

ROCALTROL

AA	+	VALIDUS PHARMS	1UGM/ML	N21068 001	Nov 20, 1998	Mar	CAHN
----	---	----------------	---------	------------	--------------	-----	------

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

		TORRENT PHARMS	100MG	N77272 001	Dec 07, 2005	Apr	CAHN
AB			200MG	N77272 002	Dec 07, 2005	Apr	CAHN
			300MG	N77272 003	Dec 07, 2005	Apr	CAHN
			400MG	N77272 004	Dec 07, 2005	Apr	CAHN

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

AB		TORRENT PHARMS	100MG	N75712 001	Jul 05, 2001	Jan	CAHN
----	--	----------------	-------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	TARO	100MG	N78115 001	Mar 31, 2009	Mar	NEWA
AB		200MG	N78115 002	Mar 31, 2009	Mar	NEWA
AB		400MG	N78115 003	Mar 31, 2009	Mar	NEWA
TEGRETOL-XR						
AB	NOVARTIS	100MG	N20234 001	Mar 25, 1996	Mar	CFTG
AB		200MG	N20234 002	Mar 25, 1996	Mar	CFTG
AB	+	400MG	N20234 003	Mar 25, 1996	Mar	CFTG

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN

@	PFIZER	EQ 382MG BASE	N50435 001		Mar	DISC
---	--------	---------------	------------	--	-----	------

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

@	SANDOZ	10MG;100MG	N73586 001	Jun 29, 1995	Mar	DISC
@		25MG;100MG	N73587 001	Jun 29, 1995	Mar	DISC
@		25MG;250MG	N73620 001	Jun 29, 1995	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

@	KV PHARM	50MG;200MG	N76663 001	Jun 24, 2004	Apr	DISC
---	----------	------------	------------	--------------	-----	------

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	+	WATSON LABS	50MG/VIAL	N76162 001	Oct 14, 2004	Apr	CAHN
AP	+		150MG/VIAL	N76162 002	Oct 14, 2004	Apr	CAHN
AP	+		450MG/VIAL	N76162 003	Oct 14, 2004	Apr	CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP		PHARMACHEMIE BV	EQ 50MG/5ML (10MG/ML)	N77679 001	Feb 25, 2009	Feb	NEWA
AP			EQ 450MG/45ML (10MG/ML)	N77679 003	Feb 25, 2009	Feb	NEWA
AP			EQ 150MG/15ML (10MG/ML)	N77679 002	Feb 25, 2009	Feb	NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

@	SANDOZ	350MG	N81025 001	Apr 13, 1989	Mar	DISC
---	--------	-------	------------	--------------	-----	------

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

>D>	AP	+	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N50461 003		Jun	DISC
>A>			@	EQ 1GM BASE/VIAL	N50461 003		Jun	DISC
>D>	AP	+		EQ 10GM BASE/VIAL	N50461 005		Jun	DISC
>A>			@	EQ 10GM BASE/VIAL	N50461 005		Jun	DISC

CEFAZOLIN SODIUM

AP		CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	N65280 001	Mar 18, 2009	Mar	NEWA	
AP			EQ 1GM BASE/VIAL	N65280 002	Mar 18, 2009	Mar	NEWA	
AP			EQ 10GM BASE/VIAL	N65295 001	Mar 18, 2009	Mar	NEWA	
AP			EQ 20GM BASE/VIAL	N65296 001	Mar 18, 2009	Mar	NEWA	
		@	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N64033 001	Oct 31, 1993	Mar	DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

>A>	AP	ACS DOBFAR	EQ 1GM BASE/VIAL	N65414 001	Jun 12, 2009	Jun	NEWA
>A>	AP		EQ 2GM BASE/VIAL	N65414 002	Jun 12, 2009	Jun	NEWA

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

AP	+	SANDOZ	EQ 2GM BASE/VIAL	N65169 004	May 09, 2005	Mar	CRLD
----	---	--------	------------------	------------	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA		DR REDDYS LABS LTD	5MG/5ML	N78870 001	Apr 27, 2009	Apr	NEWA
----	--	--------------------	---------	------------	--------------	-----	------

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

>A>	AT	XTTRIUM	0.12%	N77789 001	Jun 18, 2009	Jun	NEWA
-----	----	---------	-------	------------	--------------	-----	------

CHLOROTHIAZIDE

TABLET; ORAL

DIURIL

@ LUNDBECK INC

250MG

N11145 004

Apr CAHN

@

500MG

N11145 002

Apr CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

DIURIL

+ LUNDBECK INC

EQ 500MG BASE/VIAL

N11145 005

Apr CAHN

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ SANDOZ

100MG

N88725 001 Aug 31, 1984 Mar DISC

@

250MG

N88726 001 Aug 31, 1984 Mar DISC

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

@ SANDOZ

250MG

N89852 001 May 04, 1988 Mar DISC

@

500MG

N89853 001 May 04, 1988 Mar DISC

AA WATSON LABS

500MG

N89859 001 May 04, 1988 Apr CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

TRILIPIX

ABBOTT LABS

EQ 45MG FENOFIBRIC ACID

N22224 001 Dec 15, 2008 Jan CTNA

+

EQ 135MG FENOFIBRIC ACID

N22224 002 Dec 15, 2008 Jan CTNA

CHYMOPAPAIN

INJECTABLE; INJECTION

CHYMODIACTIN

@ CHART MEDCL

4,000 UNITS/VIAL

N18663 002 Aug 21, 1984 Mar CAHN

@

10,000 UNITS/VIAL

N18663 001 Nov 10, 1982 Mar CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ SANDOZ

200MG

N74100 001 Jan 31, 1995 Mar DISC

@

300MG

N74100 002 Jan 31, 1995 Mar DISC

@

400MG

N74100 003 Jan 31, 1995 Mar DISC

@

800MG

N74100 004 Jan 31, 1995 Mar DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OTIC

CETRAXAL

+ LABORATORIOS SALVAT EQ 0.2% BASE

N21918 001 May 01, 2009 May NEWA

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB MYLAN

EQ 250MG BASE

N75685 002 Jun 09, 2004 Mar CMFD

AB

EQ 500MG BASE

N75685 003 Jun 09, 2004 Mar CMFD

AB

EQ 750MG BASE

N75685 001 Jun 09, 2004 Mar CMFD

@ TEVA

EQ 250MG BASE

N76136 001 Jun 09, 2004 Jan DISC

@

EQ 500MG BASE

N76136 002 Jun 09, 2004 Jan DISC

@

EQ 750MG BASE

N76136 003 Jun 09, 2004 Jan DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB AMNEAL PHARMS

EQ 10MG BASE

N77045 003 Apr 29, 2005 Feb CAHN

AB

EQ 20MG BASE

N77045 002 Apr 29, 2005 Feb CAHN

AB

EQ 40MG BASE

N77045 001 Apr 29, 2005 Feb CAHN

AB GLENMARK GENERICS

EQ 10MG BASE

N77654 001 Feb 27, 2009 Feb NEWA

AB

EQ 20MG BASE

N77654 002 Feb 27, 2009 Feb NEWA

AB

EQ 40MG BASE

N77654 003 Feb 27, 2009 Feb NEWA

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

>D> + CORIA

0.1%

N17765 001 Jun CAHN

>A> + DOW PHARM SCIENCES

0.1%

N17765 001 Jun CAHN

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

@ SANDOZ

0.1MG

N70887 001 Aug 31, 1988 Mar DISC

@

0.2MG

N70886 001 Aug 31, 1988 Mar DISC

@

0.3MG

N71294 001 Aug 31, 1988 Mar DISC

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

>D> AB DR REDDYS LABS INC

EQ 75MG BASE

N76273 001 Jan 14, 2008 Jun DISC

>A> @

EQ 75MG BASE

N76273 001 Jan 14, 2008 Jun DISC

TABLET; ORAL

PLAVIX

>D>	AB	SANOFI AVENTIS US	EQ 75MG BASE	N20839 001	Nov 17, 1997	Jun	CTEC
>A>			EQ 75MG BASE	N20839 001	Nov 17, 1997	Jun	CTEC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

	@ SANDOZ	3.75MG		N72219 001	Aug 26, 1988	Mar	DISC
--	----------	--------	--	------------	--------------	-----	------

TRANXENE

	@ LUNDBECK INC	3.75MG		N17105 001		Apr	CAHN
--	----------------	--------	--	------------	--	-----	------

	@	7.5MG		N17105 002		Apr	CAHN
--	---	-------	--	------------	--	-----	------

	@	15MG		N17105 003		Apr	CAHN
--	---	------	--	------------	--	-----	------

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

	@ SANDOZ	7.5MG		N72513 001	May 11, 1990	Mar	DISC
--	----------	-------	--	------------	--------------	-----	------

	@	15MG		N72514 001	May 11, 1990	Mar	DISC
--	---	------	--	------------	--------------	-----	------

TRANXENE

AB	LUNDBECK INC	3.75MG		N17105 006		Apr	CAHN
----	--------------	--------	--	------------	--	-----	------

AB		7.5MG		N17105 007		Apr	CAHN
----	--	-------	--	------------	--	-----	------

AB	+	15MG		N17105 008		Apr	CAHN
----	---	------	--	------------	--	-----	------

TRANXENE SD

	@ LUNDBECK INC	11.25MG		N17105 005		May	DISC
--	----------------	---------	--	------------	--	-----	------

		11.25MG		N17105 005		Apr	CAHN
--	--	---------	--	------------	--	-----	------

	@	22.5MG		N17105 004		May	DISC
--	---	--------	--	------------	--	-----	------

+		22.5MG		N17105 004		Apr	CAHN
---	--	--------	--	------------	--	-----	------

>D> CLOXACILLIN SODIUM

>D> CAPSULE; ORAL

>D> CLOXAPEN

>D>	GLAXOSMITHKLINE	EQ 250MG BASE		N61806 001		Jun	DISC
-----	-----------------	---------------	--	------------	--	-----	------

>A>	@	EQ 250MG BASE		N61806 001		Jun	DISC
-----	---	---------------	--	------------	--	-----	------

>D>	+	EQ 500MG BASE		N61806 002		Jun	DISC
-----	---	---------------	--	------------	--	-----	------

>A>	@	EQ 500MG BASE		N61806 002		Jun	DISC
-----	---	---------------	--	------------	--	-----	------

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIAICIN-C

+	STI PHARMA LLC	10MG/5ML; 30MG/5ML; 1.25MG/5ML		N88704 001	Mar 22, 1985	Apr	CAHN
---	----------------	--------------------------------	--	------------	--------------	-----	------

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP	PADDOCK	EQ 150MG BASE/VIAL		N65177 001	Mar 19, 2004	Apr	CTNA
----	---------	--------------------	--	------------	--------------	-----	------

AP	X GEN PHARMS	EQ 150MG BASE/VIAL		N64216 001	Feb 26, 1999	Apr	CTNA
----	--------------	--------------------	--	------------	--------------	-----	------

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

AN	+	TEVA PARENTERAL	10MG/ML	N75271 001	Jan 18, 2000	Apr	CAHN
----	---	-----------------	---------	------------	--------------	-----	------

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

	@ PAR PHARM	0.5MG/INH		N19722 001	Nov 05, 1996	Mar	CAHN
--	-------------	-----------	--	------------	--------------	-----	------

SPRAY, METERED; NASAL

NASCOBAL

+ PAR PHARM CO 0.5MG/SPRAY N21642 001 Jan 31, 2005 May CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

@ BAXTER HLTHCARE 100MG/VIAL N12142 001 Feb CAHN

@ 200MG/VIAL N12142 002 Feb CAHN

@ 500MG/VIAL N12142 003 Feb CAHN

@ 1GM/VIAL N12142 004 Aug 30, 1982 Feb CAHN

@ 2GM/VIAL N12142 005 Aug 30, 1982 Feb CAHN

LYOPHILIZED CYTOXAN

+ BAXTER HLTHCARE 100MG/VIAL N12142 006 Dec 05, 1985 Feb CAHN

+ 200MG/VIAL N12142 007 Dec 10, 1985 Feb CAHN

AP + 500MG/VIAL N12142 008 Jan 04, 1984 Feb CAHN

AP + 1GM/VIAL N12142 010 Sep 24, 1985 Feb CAHN

AP + 2GM/VIAL N12142 009 Dec 10, 1984 Feb CAHN

TABLET; ORAL

CYTOXAN

@ BAXTER HLTHCARE 25MG N12141 002 Feb CAHN

@ 50MG N12141 001 Feb CAHN

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

+ LUNDBECK INC 0.5MG/VIAL N50682 001 Apr CAHN

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

>D> @ TIBOTEC EQ 150MG BASE N21976 005 Dec 18, 2008 Jun CMFD

>A> EQ 150MG BASE N21976 005 Dec 18, 2008 Jun CMFD

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP WATSON LABS 500MG/VIAL N76806 001 Mar 31, 2006 Apr CAHN

AP 2GM/VIAL N76806 002 Mar 31, 2006 Apr CAHN

DEGARELIX ACETATE

POWDER; SUBCUTANEOUS

>D> DEGARELIX ACETATE

>D> FERRING EQ 80MG BASE/VIAL N22201 001 Dec 24, 2008 Jun CTNA

>D> + EQ 120MG BASE/VIAL N22201 002 Dec 24, 2008 Jun CTNA

>A> FIRMAGON

>A> FERRING EQ 80MG BASE/VIAL N22201 001 Dec 24, 2008 Jun CTNA

>A> + EQ 120MG BASE/VIAL N22201 002 Dec 24, 2008 Jun CTNA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGESTREL AND ETHINYL ESTRADIOL

@ DURAMED PHARMS BARR 0.15MG;0.03MG N75256 001 Aug 12, 1999 Feb DISC

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	+	STI PHARMA LLC	0.5MG/5ML	N84754 001		Apr	CAHN
>A>		IMPLANT; INTRAVITREAL					
>A>		OZURDEX					
>A>	+	ALLERGAN	0.7MG	N22315 001	Jun 17, 2009	Jun	NEWA

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX ST

	+	ALCON	0.05%;0.3%	N50818 001	Feb 13, 2009	Feb	NEWA
--	---	-------	------------	------------	--------------	-----	------

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

KAPIDEX

		TAKEDA PHARMS	30MG	N22287 001	Jan 30, 2009	Jan	NEWA
	+		60MG	N22287 002	Jan 30, 2009	Jan	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	+	BARR	10MG	N40361 002	Jan 31, 2001	Mar	CRLD
		DEXTROSTAT					
		@ SHIRE	5MG	N84051 001		Mar	DISC
		@	10MG	N84051 002		Mar	DISC

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 60% IN PLASTIC CONTAINER

	@	HOSPIRA	60GM/100ML	N19346 001	Jan 25, 1985	Apr	DISC
--	---	---------	------------	------------	--------------	-----	------

DIATRIZOATE MEGLUMINE

>D>		INJECTABLE; INJECTION					
>D>		RENO-60					
>D>	+	BRACCO	60%	N10040 016		Jun	DISC
>A>		@	60%	N10040 016		Jun	DISC
>D>		RENO-DIP					
>D>	+	BRACCO	30%	N10040 012		Jun	DISC
>A>		@	30%	N10040 012		Jun	DISC
		SOLUTION; URETERAL					
>D>		RENO-30					
>D>		BRACCO	30%	N10040 021		Jun	DISC
>A>		@	30%	N10040 021		Jun	DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

RENOGRAFIN-60

>D>	+	BRACCO	52%;8%	N10040 006		Jun	DISC
>A>		@	52%;8%	N10040 006		Jun	DISC

DIAZEPAM

TABLET; ORAL

DIAZEPAM

	@	SANDOZ	2MG	N70302 001	Dec 20, 1985	Mar	DISC
--	---	--------	-----	------------	--------------	-----	------

TABLET; ORAL

DIAZEPAM

@ SANDOZ	5MG	N70303 001	Dec 20, 1985	Mar	DISC
@	10MG	N70304 001	Dec 20, 1985	Mar	DISC

DICLOFENAC POTASSIUM

>A> CAPSULE; ORAL

>A> ZIPSOR

>A> + XANODYNE PHARM	25MG	N22202 001	Jun 18, 2009	Jun	NEWA
----------------------	------	------------	--------------	-----	------

>A> FOR SOLUTION; ORAL

>A> CAMBIA

>A> + KOWA PHARMS	50MG	N22165 001	Jun 17, 2009	Jun	NEWA
-------------------	------	------------	--------------	-----	------

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

AA COREPHARMA	25MG	N40828 001	Nov 05, 2008	Feb	CTEC
---------------	------	------------	--------------	-----	------

TENUATE

AA + WATSON PHARMS	25MG	N11722 002		Feb	CTEC
--------------------	------	------------	--	-----	------

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

@ SANDOZ	500MG	N74604 001	Jun 10, 1996	Mar	DISC
----------	-------	------------	--------------	-----	------

+ TEVA 500MG

N73673 001	Jul 31, 1992	Mar	CTEC
------------	--------------	-----	------

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

@ HOSPIRA	0.25MG/ML	N40206 001	Aug 28, 1998	Apr	DISC
-----------	-----------	------------	--------------	-----	------

TABLET; ORAL

DIGOXIN

>A> AB IMPAX LABS	0.125MG	N78556 001	Jul 20, 2009	Jun	NEWA
-------------------	---------	------------	--------------	-----	------

>A> AB	0.25MG	N78556 002	Jul 20, 2009	Jun	NEWA
--------	--------	------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILT-CD

AB3 APOTEX	300MG	N76151 004	May 20, 2004	Apr	CAHN
------------	-------	------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+ BARR	50MG	N80738 001		Mar	CRLD
--------	------	------------	--	-----	------

@ LNK	25MG	N87977 001	Jan 27, 1983	Mar	DISC
-------	------	------------	--------------	-----	------

@	50MG	N87978 001	Jan 27, 1983	Mar	DISC
---	------	------------	--------------	-----	------

@ SANDOZ	25MG	N80832 001		Mar	DISC
----------	------	------------	--	-----	------

@	50MG	N80832 002		Mar	DISC
---	------	------------	--	-----	------

@ VALEANT PHARM INTL	50MG	N80592 001		Mar	DISC
----------------------	------	------------	--	-----	------

@ WATSON LABS	25MG	N80728 001		Mar	DISC
---------------	------	------------	--	-----	------

@	50MG	N80727 001		Mar	DISC
---	------	------------	--	-----	------

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

@ SANDOZ	25MG	N86944 002	Apr 16, 1991	Mar	DISC
----------	------	------------	--------------	-----	------

TABLET; ORAL

DIPYRIDAMOLE

@	SANDOZ	50MG	N87562	001	Feb 25, 1992	Mar	DISC
@		75MG	N87561	001	Feb 25, 1992	Mar	DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

AB	+	ABBOTT	EQ 125MG VALPROIC ACID	N19680	001	Sep 12, 1989	Jan	CFTG
----	---	--------	------------------------	--------	-----	--------------	-----	------

DIVALPROEX SODIUM

AB		DR REDDYS LABS LTD	EQ 125MG VALPROIC ACID	N78979	001	Jan 23, 2009	Jan	NEWA
AB		ZYDUS PHARMS USA INC	EQ 125MG VALPROIC ACID	N78919	001	Jan 27, 2009	Jan	NEWA

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB		MYLAN	EQ 125MG VALPROIC ACID	N90062	001	Mar 17, 2009	Mar	NEWA
AB			EQ 250MG VALPROIC ACID	N90062	002	Mar 17, 2009	Mar	NEWA
AB			EQ 500MG VALPROIC ACID	N90062	003	Mar 17, 2009	Mar	NEWA
AB		ZYDUS PHARMS USA INC	EQ 125MG VALPROIC ACID	N77100	001	Mar 05, 2009	Feb	NEWA
AB			EQ 250MG VALPROIC ACID	N77100	002	Mar 05, 2009	Feb	NEWA
AB			EQ 500MG VALPROIC ACID	N77100	003	Mar 05, 2009	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

DEPAKOTE ER

AB		ABBOTT	EQ 250MG VALPROIC ACID	N21168	002	May 31, 2002	Jan	CFTG
AB	+		EQ 500MG VALPROIC ACID	N21168	001	Aug 04, 2000	Jan	CFTG

DIVALPROEX SODIUM

AB		ANCHEN PHARMS	EQ 250MG VALPROIC ACID	N78445	001	Feb 26, 2009	Feb	NEWA
AB		IMPAX LABS	EQ 250MG VALPROIC ACID	N78791	001	May 06, 2009	Apr	NEWA
AB		MYLAN	EQ 250MG VALPROIC ACID	N77567	001	Jan 29, 2009	Jan	NEWA
AB			EQ 500MG VALPROIC ACID	N77567	002	Jan 29, 2009	Jan	NEWA
AB		WOCKHARDT	EQ 250MG VALPROIC ACID	N78705	002	Feb 10, 2009	Jan	NEWA
AB		ZYDUS PHARMS USA INC	EQ 250MG VALPROIC ACID	N78239	001	Feb 27, 2009	Feb	NEWA

DORIPENEM

INJECTABLE; IV (INFUSION)

DORIBAX

>D>	+	JOHNSON AND JOHNSON	500MG/VIAL	N22106	001	Oct 12, 2007	Jun	CAHN
>A>	+	ORTHO MCNEIL JANSSEN	500MG/VIAL	N22106	001	Oct 12, 2007	Jun	CAHN

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT		ALCON	EQ 2% BASE	N78981	001	Apr 13, 2009	Mar	NEWA
>A>	AT	BAUSCH AND LOMB	EQ 2% BASE	N90143	001	Jun 25, 2009	Jun	NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>A>	AT	BAUSCH AND LOMB	EQ 2% BASE;EQ 0.5% BASE	N90037	001	Jul 14, 2009	Jun	NEWA
-----	----	-----------------	-------------------------	--------	-----	--------------	-----	------

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

+	PAR PHARM	EQ 150MG BASE	N65055	003	Jul 15, 2005	Jan	CRLD
---	-----------	---------------	--------	-----	--------------	-----	------

TABLET; ORAL

DOXYCYCLINE

AB		MUTUAL PHARM	EQ 50MG BASE	N65471	001	Apr 17, 2009	Mar	NEWA
----	--	--------------	--------------	--------	-----	--------------	-----	------

TABLET; ORAL

DOXYCYCLINE

AB	MUTUAL PHARM	EQ 75MG BASE	N65471 002	Apr 17, 2009	Mar	NEWA
AB		EQ 100MG BASE	N65471 003	Apr 17, 2009	Mar	NEWA

DRONABINOL

CAPSULE; ORAL

DRONABINOL

AB	SVC PHARMA	2.5MG	N78292 001	Jun 27, 2008	Mar	CAHN
AB		5MG	N78292 002	Jun 27, 2008	Mar	CAHN
AB		10MG	N78292 003	Jun 27, 2008	Mar	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	BARR	3MG;0.02MG	N78515 001	Mar 30, 2009	Mar	NEWA
AB	YAZ					
AB	+ BAYER HLTHCARE	3MG;0.02MG	N21676 001	Mar 16, 2006	Mar	CFTG

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON

>D>	@ BIONICHE PHARMA	10MG/ML	N88873 001	Aug 06, 1985	Jun	CMFD
>A>	AP	10MG/ML	N88873 001	Aug 06, 1985	Jun	CMFD

EFAVIRENZ

CAPSULE; ORAL

SUSTIVA

>D>	BRISTOL MYERS SQUIBB	100MG	N20972 002	Sep 17, 1998	Jun	DISC
>A>	@	100MG	N20972 002	Sep 17, 1998	Jun	DISC

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

@ SANDOZ

@

@

@

2.5MG
5MG
10MG
20MG

N75048 001 Aug 22, 2000 Mar DISC
N75048 002 Aug 22, 2000 Mar DISC
N75048 003 Aug 22, 2000 Mar DISC
N75048 004 Aug 22, 2000 Mar DISC

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

@ ASTRAZENECA

5MG;2.5MG

N20668 002 Oct 28, 1998 May DISC

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP	+ HOSPIRA	1.25MG/ML	N75458 001	Aug 22, 2000	Feb	CRLD
	VASOTEC					
	@ BIOVAIL LABS INTL	1.25MG/ML	N19309 001	Feb 09, 1988	Feb	DISC

EPINEPHRINE

INJECTABLE; IM-SC

TWINJECT 0.15

>A>	+ SCIELE PHARMA INC	EQ 0.15MG /DELIVERY	N20800 002	May 28, 2004	Jun	CAHN
>D>	+ VERUS PHARMS	EQ 0.15MG /DELIVERY	N20800 002	May 28, 2004	Jun	CAHN

INJECTABLE; IM-SC

TWINJECT 0.3

>A>	+	SCIELE PHARMA INC	EQ 0.3MG /DELIVERY	N20800 001	May 30, 2003	Jun	CAHN
>D>	+	VERUS PHARMS	EQ 0.3MG /DELIVERY	N20800 001	May 30, 2003	Jun	CAHN

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

	+	DENTSPLY PHARM	0.005MG/ML;4%	N21383 001		Apr	CTNA
--	---	----------------	---------------	------------	--	-----	------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE DENTAL WITH EPINEPHRINE

AP	+	DENTSPLY PHARM	0.01MG/ML;2%	N21381 001		Apr	CTNA
----	---	----------------	--------------	------------	--	-----	------

AP	+		0.02MG/ML;2%	N21381 002		Apr	CTNA
----	---	--	--------------	------------	--	-----	------

XYLOCAINE W/ EPINEPHRINE

AP	+	APP PHARMS	0.02MG/ML;2%	N06488 005		Apr	CMFD
----	---	------------	--------------	------------	--	-----	------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

>A>	AP	AKORN INC	50MG/25ML (2MG/ML)	N90163 001	Jun 24, 2009	Jun	NEWA
-----	----	-----------	--------------------	------------	--------------	-----	------

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

	+	ACTELION	EQ 1.5MG BASE/VIAL	N22260 001	Jun 27, 2008	Apr	CAHN
--	---	----------	--------------------	------------	--------------	-----	------

ERGOCALCIFEROL

CAPSULE; ORAL

ERGOCALCIFEROL

AA		ORIT LABS LLC	50,000 IU	N40833 001	May 20, 2009	May	NEWA
----	--	---------------	-----------	------------	--------------	-----	------

ERYTHROMYCIN

OINTMENT; TOPICAL

AKNE-MYCIN

>D>	+	CORIA	2%	N50584 001	Jan 10, 1985	Jun	CAHN
-----	---	-------	----	------------	--------------	-----	------

>A>	+	DOW PHARM SCIENCES	2%	N50584 001	Jan 10, 1985	Jun	CAHN
-----	---	--------------------	----	------------	--------------	-----	------

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

	@	ALPHARMA US PHARMS	EQ 125MG BASE/5ML	N62353 001	Nov 18, 1982	Apr	DISC
--	---	--------------------	-------------------	------------	--------------	-----	------

	@		EQ 250MG BASE/5ML	N62409 001	Dec 16, 1982	Apr	DISC
--	---	--	-------------------	------------	--------------	-----	------

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

	@	ALPHARMA US PHARMS	EQ 200MG BASE/5ML	N62200 001		Apr	DISC
--	---	--------------------	-------------------	------------	--	-----	------

	@		EQ 400MG BASE/5ML	N62200 002		Apr	DISC
--	---	--	-------------------	------------	--	-----	------

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

>D>	@	BARR	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N62759 001	May 20, 1988	Jun	CMFD
-----	---	------	--	------------	--------------	-----	------

GRANULE; ORAL

		ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL						
>A>	+	BARR	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N62759 001	May 20, 1988	Jun	CMFD	
		ERYZOLE						
	@	ALRA	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N62758 001	Jun 15, 1988	Jan	DISC	
		PEDIAZOLE						
	@	ROSS LABS	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N50529 001		Jan	DISC	

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

		ERYTHROCIN						
	@	HOSPIRA	EQ 1GM BASE/VIAL	N50182 003		Feb	DISC	
AP	+		EQ 1GM BASE/VIAL	N62638 002	Oct 31, 1986	Feb	CRLD	

ESTRADIOL

TABLET; ORAL

INNOFEM

	@	NOVO NORDISK INC	0.5MG	N40312 001	Nov 19, 1999	Apr	DISC	
	@		1MG	N40312 002	Nov 19, 1999	Apr	DISC	
	@		2MG	N40312 003	Nov 19, 1999	Apr	DISC	

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

>A>	AB	LUPIN	100MG	N78939 001	Jun 17, 2009	Jun	NEWA	
>A>	AB		400MG	N78939 002	Jun 17, 2009	Jun	NEWA	
		MYAMBUTOL						
AB		STI PHARMA LLC	100MG	N16320 001		Mar	CAHN	
	@		200MG	N16320 002		Mar	CAHN	
AB			400MG	N16320 003		Mar	CAHN	
	@		500MG	N16320 004		Mar	CAHN	

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

DEMULEN 1/35-21

	@	GD SEARLE LLC	0.035MG;1MG	N18168 001		Apr	DISC	
--	---	---------------	-------------	------------	--	-----	------	--

DEMULEN 1/50-21

	@	GD SEARLE LLC	0.05MG;1MG	N16927 001		Apr	DISC	
--	---	---------------	------------	------------	--	-----	------	--

ZOVIA 1/35E-21

	@	WATSON LABS	0.035MG;1MG	N72720 001	Dec 30, 1991	Apr	DISC	
--	---	-------------	-------------	------------	--------------	-----	------	--

ZOVIA 1/50E-21

	@	WATSON LABS	0.05MG;1MG	N72722 001	Dec 30, 1991	Apr	DISC	
--	---	-------------	------------	------------	--------------	-----	------	--

TABLET; ORAL-28

DEMULEN 1/35-28

	@	GD SEARLE LLC	0.035MG;1MG	N18160 001		Apr	DISC	
--	---	---------------	-------------	------------	--	-----	------	--

DEMULEN 1/50-28

	@	GD SEARLE LLC	0.05MG;1MG	N16936 001		Apr	DISC	
--	---	---------------	------------	------------	--	-----	------	--

ZOVIA 1/50E-28

+		WATSON LABS	0.05MG;1MG	N72723 001	Dec 30, 1991	Apr	CRLD	
---	--	-------------	------------	------------	--------------	-----	------	--

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

TRIPHASIL-21

@ AKRIMAX PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075	N19192 001	Nov 01, 1984	Apr	CAHN
	MG,0.125MG				

TABLET; ORAL-28

TRIPHASIL-28

@ WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075	N19190 001	Nov 01, 1984	Apr	DISC
	MG,0.125MG				

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71041 001	Sep 24, 1991	Apr	CRLD
-------------	---------------------------	------------	--------------	-----	------

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71044 001	Apr 01, 1988	Apr	CTEC
-------------	---------------------------	------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

LOESTRIN 21 1.5/30

AB	WARNER CHILCOTT	0.03MG;1.5MG	N17875 001		Apr	CRLD
----	-----------------	--------------	------------	--	-----	------

LOESTRIN 21 1/20

AB	WARNER CHILCOTT	0.02MG;1MG	N17876 001		Apr	CRLD
----	-----------------	------------	------------	--	-----	------

TABLET; ORAL-28

LOESTRIN FE 1/20

AB	WARNER CHILCOTT	0.02MG;1MG	N17354 001		Apr	CRLD
----	-----------------	------------	------------	--	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ORTHO TRI-CYCLEN LO

>D>	+	ORTHO MCNEIL JANSSEN	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	N21241 001	Aug 22, 2002	Jun	CFTG
-----	---	----------------------	---	------------	--------------	-----	------

>A>	AB	+	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	N21241 001	Aug 22, 2002	Jun	CFTG
-----	----	---	---	------------	--------------	-----	------

>A>		TRI LO SPRINTC					
-----	--	----------------	--	--	--	--	--

>A>	AB	BARR	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	N76784 001	Jun 29, 2009	Jun	NEWA
-----	----	------	---	------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

OGESTREL 0.5/50-21

@ WATSON LABS	0.05MG;0.5MG	N75406 001	Dec 15, 1999	Apr	DISC
---------------	--------------	------------	--------------	-----	------

OVRAL

@ AKRIMAX PHARMS	0.05MG;0.5MG	N16672 001		Mar	CAHN
------------------	--------------	------------	--	-----	------

ETHOTOIN

TABLET; ORAL

PEGANONE

+	LUNDBECK INC	250MG	N10841 001		Apr	CAHN
---	--------------	-------	------------	--	-----	------

@		500MG	N10841 003		Apr	CAHN
---	--	-------	------------	--	-----	------

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

+	GENPHARM	50MG	N75635 001	Sep 19, 2001	Feb	CRLD
---	----------	------	------------	--------------	-----	------

CAPSULE; ORAL

VEPESID

@ BRISTOL MYERS SQUIBB 50MG

N19557 001 Dec 30, 1986 Feb DISC

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS

5MG

N22334 001 Mar 30, 2009 Mar NEWA

+

10MG

N22334 002 Mar 30, 2009 Mar NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

AB ALEMBIC LTD

20MG

N78916 001 May 22, 2009 May NEWA

AB

40MG

N78916 002 May 22, 2009 May NEWA

@ SANDOZ

20MG

N75302 001 Apr 16, 2001 Mar DISC

@

40MG

N75302 002 Apr 16, 2001 Mar DISC

FEBUXOSTAT

TABLET; ORAL

ULORIC

TAKEDA PHARMS

40MG

N21856 001 Feb 13, 2009 Feb NEWA

+

80MG

N21856 002 Feb 13, 2009 Feb NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

@ PEDINOL

EQ 300MG BASE

N17604 002

Feb DISC

NALFON 200

+ PEDINOL

EQ 200MG BASE

N17604 003

Feb CRLD

TABLET; ORAL

FENOPROFEN CALCIUM

@ SANDOZ

EQ 600MG BASE

N72396 001 Oct 17, 1988 Mar DISC

FENTANYL CITRATE

INJECTABLE; INJECTION

SUBLIMAZE PRESERVATIVE FREE

AP + AKORN

EQ 0.05MG BASE/ML

N16619 001

May CAHN

>A> FERUMOXYTOL

>A> SOLUTION; INTRAVENOUS

>A> FERAHEME

>A> + AMAG PHARMS INC EQ 510MG IRON/17ML (EQ 30MG IRON/ML)

N22180 001 Jun 30, 2009 Jun NEWA

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

>A> AB APOTEX INC

50MG

N79164 001 Jul 09, 2009 Jun NEWA

>A> AB

100MG

N79164 002 Jul 09, 2009 Jun NEWA

>A> AB

150MG

N79164 003 Jul 09, 2009 Jun NEWA

@ SANDOZ

50MG

N76030 001 Oct 28, 2002 Mar DISC

@

100MG

N76030 002 Oct 28, 2002 Mar DISC

@

150MG

N76030 003 Oct 28, 2002 Mar DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

>D>	AP	+	BAYER HLTHCARE	50MG/VIAL	N20038	001	Apr 18, 1991	Jun	CAHN
>A>	AP	+	GENZYME	50MG/VIAL	N20038	001	Apr 18, 1991	Jun	CAHN
			FLUDARABINE PHOSPHATE						
	AP		ACTAVIS TOTOWA	50MG/VIAL	N78610	001	Feb 11, 2009	Feb	NEWA
			TABLET; ORAL						
			FLUDARABINE PHOSPHATE						
>D>		+	ANTISOMA	10MG	N22273	001	Dec 18, 2008	Jun	CAHN
>A>		+	SANOFI AVENTIS US	10MG	N22273	001	Dec 18, 2008	Jun	CAHN

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

	AP		HIKMA FARMACEUTICA	0.5MG/5ML (0.1MG/ML)	N78527	001	Mar 23, 2009	Mar	NEWA
	AP			1MG/10ML (0.1MG/ML)	N78527	002	Mar 23, 2009	Mar	NEWA

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

DERMA-SMOOTH/FS

		+	HILL DERMAC	0.01%	N19452	002	Nov 09, 2005	Feb	NEWA
--	--	---	-------------	-------	--------	-----	--------------	-----	------

SHAMPOO; TOPICAL

>A>			CAPEX						
>A>		+	GALDERMA LABS LP	0.01%	N20001	001	Aug 27, 1990	Jun	CTNA
>D>			FS						
>D>		+	GALDERMA LABS LP	0.01%	N20001	001	Aug 27, 1990	Jun	CTNA

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRASONE

>D>		+	ALCON	0.1%;0.3%	N50628	001	Jul 21, 1989	Jun	DISC
>A>		@		0.1%;0.3%	N50628	001	Jul 21, 1989	Jun	DISC

FLUOROURACIL

SOLUTION; TOPICAL

FLUOROPLEX

		@	ELORAC	1%	N16765	001		Feb	CAHN
--	--	---	--------	----	--------	-----	--	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

	AB1		ALEMBIC LTD	EQ 10MG BASE	N90223	001	Mar 19, 2009	Mar	NEWA
	AB1			EQ 20MG BASE	N90223	002	Mar 19, 2009	Mar	NEWA
	AB			EQ 40MG BASE	N90223	003	Mar 19, 2009	Mar	NEWA
	AB1		BEIJING DOUBLE CRANE	EQ 10MG BASE	N76165	001	Feb 01, 2002	Mar	CAHN
	AB1			EQ 20MG BASE	N76165	002	Feb 01, 2002	Mar	CAHN

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

	AA		AUROBINDO PHARM	EQ 20MG BASE/5ML	N79209	001	Mar 20, 2009	Mar	NEWA
>D>			PROZAC						
>D>	AA	+	LILLY	EQ 20MG BASE/5ML	N20101	001	Apr 24, 1991	Jun	DISC
>A>		@		EQ 20MG BASE/5ML	N20101	001	Apr 24, 1991	Jun	DISC

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

AB	MYLAN	EQ 10MG BASE	N75755 001	Aug 02, 2001	Apr	CAHN
	+	EQ 20MG BASE	N75755 002	Aug 02, 2001	Apr	CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

	@ SANDOZ	15MG	N71716 001	Jul 31, 1991	Mar	DISC
	@	30MG	N71717 001	Jul 31, 1991	Mar	DISC

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

	@ SANDOZ	50MG	N74448 001	Jul 28, 1995	Mar	DISC
	@	100MG	N74448 002	Jul 28, 1995	Mar	DISC

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

	@ IVAX PHARMS	25MG	N75898 001	Mar 12, 2001	Mar	DISC
	@	50MG	N75898 002	Mar 12, 2001	Mar	DISC
	@	100MG	N75898 003	Mar 12, 2001	Mar	DISC

FOLIC ACID

TABLET; ORAL

FOLIC ACID

>A>	AA	INVAGEN PHARMS	1MG	N90035 001	Jun 09, 2009	Jun	NEWA
-----	----	----------------	-----	------------	--------------	-----	------

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

AP	GENERAMEDIX	1.5GM/1.5ML (1GM/ML)	N79033 001	Apr 07, 2009	Mar	NEWA
----	-------------	----------------------	------------	--------------	-----	------

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL

MONUROL

>D>	+	ZAMBON	EQ 3GM BASE/PACKET	N50717 001	Dec 19, 1996	Jun	CAHN
>A>	+	ZAMBON SPA	EQ 3GM BASE/PACKET	N50717 001	Dec 19, 1996	Jun	CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

	@ SANDOZ	10MG	N76188 001	Oct 08, 2004	Mar	DISC	
	@	20MG	N76188 002	Oct 08, 2004	Mar	DISC	
	@	40MG	N76188 003	Oct 08, 2004	Mar	DISC	
>D>	AB	TEVA	40MG	N76139 003	Nov 25, 2003	Jun	CRLD
>A>	AB	+	40MG	N76139 003	Nov 25, 2003	Jun	CRLD

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>A>	AB	AUROBINDO PHARMA	10MG;12.5MG	N79245 001	Jul 09, 2009	Jun	NEWA
>A>	AB		20MG;12.5MG	N79245 002	Jul 09, 2009	Jun	NEWA
>A>	AB	INVAGEN PHARMS	10MG;12.5MG	N90228 001	Jul 09, 2009	Jun	NEWA
>A>	AB		20MG;12.5MG	N90228 002	Jul 09, 2009	Jun	NEWA

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>D>	AB	TEVA	20MG;12.5MG	N76945 002	Jul 05, 2006	Jun	CRLD
>A>	AB	+	20MG;12.5MG	N76945 002	Jul 05, 2006	Jun	CRLD
		MONOPRIL-HCT					
		@ BRISTOL MYERS SQUIBB	10MG;12.5MG	N20286 002	Nov 30, 1994	Feb	DISC
		@	20MG;12.5MG	N20286 001	Nov 30, 1994	Feb	DISC

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

>A>	AB	IPCA LABS LTD	20MG	N78010 001	Sep 18, 2006	Jun	CAHN
>A>	AB		40MG	N78010 002	Sep 18, 2006	Jun	CAHN
>A>	AB		80MG	N78010 003	Sep 18, 2006	Jun	CAHN
>D>	AB	OHM LABS	20MG	N78010 001	Sep 18, 2006	Jun	CAHN
>D>	AB		40MG	N78010 002	Sep 18, 2006	Jun	CAHN
>D>	AB		80MG	N78010 003	Sep 18, 2006	Jun	CAHN

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB		IMPAX LABS	EQ 8MG BASE	N78484 001	May 27, 2009	May	NEWA
AB			EQ 16MG BASE	N78484 002	May 27, 2009	May	NEWA
AB			EQ 24MG BASE	N78484 003	May 27, 2009	May	NEWA

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

AA		ROXANE	4MG/ML	N78185 001	Jan 30, 2009	Jan	NEWA
AA		RAZADYNE					
AA		+ ORTHO MCNEIL JANSSEN	4MG/ML	N21224 001	Jun 22, 2001	Jan	CFTG

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB		BEJING YABAO	EQ 4MG BASE	N77604 001	Feb 06, 2009	Apr	CAHN
AB			EQ 8MG BASE	N77604 002	Feb 06, 2009	Apr	CAHN
AB			EQ 12MG BASE	N77604 003	Feb 06, 2009	Apr	CAHN
AB		MYLAN	EQ 4MG BASE	N77590 001	May 29, 2009	May	NEWA
AB			EQ 4MG BASE	N77603 001	Aug 28, 2008	Apr	CAHN
AB			EQ 8MG BASE	N77590 002	May 29, 2009	May	NEWA
AB			EQ 8MG BASE	N77603 002	Aug 28, 2008	Apr	CAHN
AB			EQ 12MG BASE	N77590 003	May 29, 2009	May	NEWA
AB			EQ 12MG BASE	N77603 003	Aug 28, 2008	Apr	CAHN
AB		PAR PHARM	EQ 4MG BASE	N77604 001	Feb 06, 2009	Jan	NEWA
AB			EQ 8MG BASE	N77604 002	Feb 06, 2009	Jan	NEWA
AB			EQ 12MG BASE	N77604 003	Feb 06, 2009	Jan	NEWA
AB		ROXANE	EQ 4MG BASE	N77608 001	Feb 11, 2009	Jan	NEWA
AB			EQ 8MG BASE	N77608 002	Feb 11, 2009	Jan	NEWA
AB			EQ 12MG BASE	N77608 003	Feb 11, 2009	Jan	NEWA
>A>	AB	SANDOZ	EQ 4MG BASE	N77589 001	Jun 22, 2009	Jun	NEWA
>A>	AB		EQ 8MG BASE	N77589 002	Jun 22, 2009	Jun	NEWA
>A>	AB		EQ 12MG BASE	N77589 003	Jun 22, 2009	Jun	NEWA
>A>	AB	TEVA PHARMS	EQ 4MG BASE	N77587 001	Jul 09, 2009	Jun	NEWA
>A>	AB		EQ 8MG BASE	N77587 002	Jul 09, 2009	Jun	NEWA
>A>	AB		EQ 12MG BASE	N77587 003	Jul 09, 2009	Jun	NEWA

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

>D>		CYTOVENE							
>A>		@ ROCHE PALO	EQ 500MG BASE/VIAL	N19661	001	Jun 23, 1989	Jun	DISC	
>D>		CYTOVENE IV							
>D>	AP	+ ROCHE PALO	EQ 500MG BASE/VIAL	N19661	001	Jun 23, 1989	Jun	DISC	
		GANCICLOVIR SODIUM							
>D>	AP	BEDFORD	EQ 500MG BASE/VIAL	N76222	001	Jul 16, 2003	Jun	CRLD	
>A>		+	EQ 500MG BASE/VIAL	N76222	001	Jul 16, 2003	Jun	CRLD	

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

	+	TAKEDA GLOBAL	2MG;30MG	N21925	001	Jul 28, 2006	May	CRLD	
			4MG;30MG	N21925	002	Jul 28, 2006	May	CRLD	

GLYBURIDE

TABLET; ORAL

GLYBURIDE

AB	+	TEVA	5MG	N74388	003	Aug 29, 1995	Mar	CRLD	
		MICRONASE							
		@ PHARMACIA AND UPJOHN	1.25MG	N17498	001	May 01, 1984	Mar	DISC	
		@	2.5MG	N17498	002	May 01, 1984	Mar	DISC	
		@	5MG	N17498	003	May 01, 1984	Mar	DISC	

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

AB	+	BRISTOL MYERS SQUIBB	2.5MG;500MG	N21178	002	Jul 31, 2000	May	CRLD	
AB			5MG;500MG	N21178	003	Jul 31, 2000	May	CRLD	
		GLYBURIDE AND METFORMIN HYDROCHLORIDE							
AB		DR REDDYS LABS INC	1.25MG;250MG	N79009	001	Jun 03, 2009	May	NEWA	
AB			2.5MG;500MG	N79009	002	Jun 03, 2009	May	NEWA	
AB			5MG;500MG	N79009	003	Jun 03, 2009	May	NEWA	

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA		WEST WARD	1MG	N40836	001	Mar 05, 2009	Feb	NEWA	
AA			2MG	N40836	002	Mar 05, 2009	Feb	NEWA	

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N78534	001	Apr 30, 2009	Apr	NEWA	
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N78531	001	Apr 30, 2009	Apr	NEWA	
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N78531	002	Apr 30, 2009	Apr	NEWA	

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

AB		DR REDDYS LABS LTD	EQ 1MG BASE	N78846	001	Feb 27, 2009	Feb	NEWA	
>A>	AB	NATCO PHARMA	EQ 1MG BASE	N78969	001	Jun 22, 2009	Jun	NEWA	

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

>A>	AB	MYLAN	10MG	N70278 002	Jul 16, 2009	Jun	NEWA
>A>	AB		20MG	N70278 003	Jul 16, 2009	Jun	NEWA

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

@ SANDOZ

EQ 50MG BASE/ML

N76463 001 Jun 24, 2005 Apr DISC

@

EQ 100MG BASE/ML

N76463 002 Jun 24, 2005 Apr DISC

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

@ SANDOZ

EQ 5MG BASE/ML

N76464 001 Sep 29, 2004 Apr DISC

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

+ ENDO PHARM

50MG

N22058 001 May 03, 2007 Apr CAHN

VANTAS

+ ENDO PHARM

50MG

N21732 001 Oct 12, 2004 Apr CAHN

+ ENDO PHARMS

50MG

N21732 001 Oct 12, 2004 Mar CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

@ ENDO PHARMS

1.5MG/5ML; 5MG/5ML

N05213 002 Jul 26, 1988 Feb DISC

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA + HI TECH PHARMA

1.5MG/5ML; 5MG/5ML

N40613 001 Feb 08, 2008 Feb CRLD

TABLET; ORAL

HYCODAN

@ ENDO PHARMS

1.5MG; 5MG

N05213 001 Jul 26, 1988 Feb DISC

TUSSIGON

AA + KING PHARMS

1.5MG; 5MG

N88508 001 Jul 30, 1985 Feb CRLD

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP AKORN

20MG/ML

N40730 001 Apr 21, 2009 Mar NEWA

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA GLENMARK PHARMS LTD

10MG

N90527 001 May 27, 2009 May NEWA

AA

25MG

N90527 002 May 27, 2009 May NEWA

AA

50MG

N90527 003 May 27, 2009 May NEWA

AA

100MG

N90527 004 May 27, 2009 May NEWA

@ SANDOZ

10MG

N83241 001 Mar DISC

@

25MG

N83560 001 Mar DISC

@

50MG

N83561 001 Mar DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB IPCA LABS LTD

12.5MG

N79237 001 Apr 02, 2009 Mar NEWA

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

@ ROXANE	50MG/5ML	N88587 001	Jul 02, 1984	Mar	DISC
----------	----------	------------	--------------	-----	------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@ SANDOZ	25MG	N87565 001	Mar 09, 1982	Mar	DISC
@	50MG	N84912 001		Mar	DISC

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ SANDOZ	25MG;40MG	N71060 001	Aug 26, 1987	Mar	DISC
@	25MG;80MG	N71061 001	Aug 26, 1987	Mar	DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	RANBAXY	12.5MG;EQ 10MG BASE	N78211 001	Mar 04, 2009	Feb	NEWA
AB		12.5MG;EQ 20MG BASE	N78211 002	Mar 04, 2009	Feb	NEWA
AB		25MG;EQ 20MG BASE	N78211 003	Mar 04, 2009	Feb	NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

@ SANDOZ	25MG;25MG	N86881 001		Mar	DISC
----------	-----------	------------	--	-----	------

HYDROCORTISONE

LOTION; TOPICAL

>D>	CETACORT				
>D>	CORIA	0.5%	N80426 002		Jun DISC
>A>	@	0.5%	N80426 002		Jun DISC
>D>	AT	1%	N80426 001		Jun DISC
>A>	@	1%	N80426 001		Jun DISC

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION; OPHTHALMIC

TERRA-CORTRIL

@ PFIZER	1.5%;EQ 5MG BASE/ML	N61016 001		Feb	DISC
----------	---------------------	------------	--	-----	------

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

PROCTOFOAM HC

BX	UCB INC	1%;1%	N86195 001		Apr CAHN
----	---------	-------	------------	--	----------

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

AT	+ NYCOMED US	1%;10%	N80505 001		Apr CAHN
----	--------------	--------	------------	--	----------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

+	PURDUE PHARM PRODS	1MG/ML	N19034 003	Apr 30, 2009	May	CMFD
		1MG/ML	N19034 003	Apr 30, 2009	Apr	NEWA
+		2MG/ML	N19034 004	Apr 30, 2009	May	CRLD
		2MG/ML	N19034 004	Apr 30, 2009	Apr	NEWA

INJECTABLE; INJECTION

DILAUDID

+ PURDUE PHARM PRODS	4MG/ML	N19034 005	Apr 30, 2009	May	CRLD
	4MG/ML	N19034 005	Apr 30, 2009	Apr	NEWA

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB ROXANE	4MG	N74597 003	May 29, 2009	May	NEWA
-----------	-----	------------	--------------	-----	------

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

AB BARR	500MG	N75143 001	Oct 16, 1998	Feb	CMFD
---------	-------	------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

>D> AP	ABRAXIS PHARM	25MG/ML	N87329 001		Jun	CRLD
>A> AP	+	25MG/ML	N87329 001		Jun	CRLD
>D> AP		50MG/ML	N87329 002		Jun	CRLD
>A> AP	+	50MG/ML	N87329 002		Jun	CRLD

VISTARIL

>D> AP	+	PFIZER	25MG/ML	N11111 001		Jun	DISC
>A>	@		25MG/ML	N11111 001		Jun	DISC
>D> AP	+		50MG/ML	N11111 002		Jun	DISC
>A>	@		50MG/ML	N11111 002		Jun	DISC

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ SANDOZ	10MG	N87869 001	Dec 20, 1982	Mar	DISC
@	25MG	N87870 001	Dec 20, 1982	Mar	DISC
@	50MG	N87871 001	Dec 20, 1982	Mar	DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

@ SANDOZ	EQ 25MG HCL	N81127 001	Jun 28, 1991	Mar	DISC
----------	-------------	------------	--------------	-----	------

IBUPROFEN

>A>	SOLUTION; INTRAVENOUS					
>A>	CALDOLOR					
>A>	CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N22348 001	Jun 11, 2009	Jun	NEWA
>A>	+	800MG/8ML (100MG/ML)	N22348 002	Jun 11, 2009	Jun	NEWA

TABLET; ORAL

IBUPROFEN

AB	+	DR REDDYS LA	800MG	N75682 003	Nov 14, 2001	Feb	CRLD
		@ SANDOZ	300MG	N70734 001	Jun 12, 1986	Mar	DISC
		@	400MG	N70735 001	Jun 12, 1986	Mar	DISC
		@	600MG	N70736 001	Jun 12, 1986	Mar	DISC
		@	800MG	N72169 001	Dec 11, 1987	Mar	DISC
AB		SHASUN USA	400MG	N78329 001	Feb 05, 2009	Jan	NEWA
AB			600MG	N78329 002	Feb 05, 2009	Jan	NEWA
AB			800MG	N78329 003	Feb 05, 2009	Jan	NEWA

MOTRIN

@ MCNEIL CONSUMER	300MG	N17463 003		Apr	DISC
@	400MG	N17463 002		Feb	DISC
@	600MG	N17463 004		Feb	DISC
@	800MG	N17463 005	May 22, 1985	Feb	DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+	LUNDBECK INC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N21903 001	Apr 13, 2006	Apr	CAHN
---	--------------	---------------------------------------	------------	--------------	-----	------

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

@	BAXTER HLTHCARE	1GM/VIAL	N19763 001	Dec 30, 1988	Feb	CAHN
---	-----------------	----------	------------	--------------	-----	------

@		3GM/VIAL	N19763 002	Dec 30, 1988	Feb	CAHN
---	--	----------	------------	--------------	-----	------

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

+	BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N19763 003	Oct 10, 1992	Feb	CAHN
---	-----------------	-------------------	------------	--------------	-----	------

+		3GM/VIAL;100MG/ML	N19763 004	Oct 10, 1992	Feb	CAHN
---	--	-------------------	------------	--------------	-----	------

ILOPERIDONE

TABLET; ORAL

FANAPT

	VANDA PHARMS INC	1MG	N22192 001	May 06, 2009	May	NEWA
--	------------------	-----	------------	--------------	-----	------

		2MG	N22192 002	May 06, 2009	May	NEWA
--	--	-----	------------	--------------	-----	------

		4MG	N22192 003	May 06, 2009	May	NEWA
--	--	-----	------------	--------------	-----	------

		6MG	N22192 004	May 06, 2009	May	NEWA
--	--	-----	------------	--------------	-----	------

		8MG	N22192 005	May 06, 2009	May	NEWA
--	--	-----	------------	--------------	-----	------

		10MG	N22192 006	May 06, 2009	May	NEWA
--	--	------	------------	--------------	-----	------

+		12MG	N22192 007	May 06, 2009	May	NEWA
---	--	------	------------	--------------	-----	------

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

>D>	MERCK	EQ 333MG BASE	N20685 005	Dec 17, 1998	Jun	DISC
-----	-------	---------------	------------	--------------	-----	------

>A>	@	EQ 333MG BASE	N20685 005	Dec 17, 1998	Jun	DISC
-----	---	---------------	------------	--------------	-----	------

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

AB	+	SANDOZ	75MG	N74464 001	May 28, 1998	Feb	CTEC
----	---	--------	------	------------	--------------	-----	------

AB		AVANTHI INC	75MG	N79175 001	Mar 06, 2009	Feb	NEWA
----	--	-------------	------	------------	--------------	-----	------

--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--

+	IROKO PHARMS	25MG/5ML	N18332 001	Oct 10, 1985	Mar	CAHN
---	--------------	----------	------------	--------------	-----	------

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP	+	LUNDBECK INC	EQ 1MG BASE/VIAL	N18878 001	Jan 30, 1985	Apr	CAHN
----	---	--------------	------------------	------------	--------------	-----	------

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

	SANOFI AVENTIS US	300 UNITS/3ML	N21629 003	Feb 24, 2009	Feb	NEWA
--	-------------------	---------------	------------	--------------	-----	------

INSULIN RECOMBINANT HUMAN

>D>	POWDER; INHALATION						
>D>	EXUBERA						
>D>	PFIZER	1MG/INH	N21868	001	Jan 27, 2006	Jun	DISC
>A>	@	1MG/INH	N21868	001	Jan 27, 2006	Jun	DISC
>D>	+	3MG/INH	N21868	002	Jan 27, 2006	Jun	DISC
>A>	@	3MG/INH	N21868	002	Jan 27, 2006	Jun	DISC

IPRATROPIUM BROMIDE

	SOLUTION; INHALATION						
	IPRATROPIUM BROMIDE						
AN	TEVA PARENTERAL	0.02%	N75313	001	Feb 07, 2000	Apr	CAHN

IRINOTECAN HYDROCHLORIDE

	INJECTABLE; INJECTION						
	IRINOTECAN HYDROCHLORIDE						
AP	PHARMAFORCE	40MG/2ML (20MG/ML)	N90016	001	Jan 28, 2009	Mar	NEWA
AP		40MG/2ML (20MG/ML)	N90016	001	Jan 28, 2009	Jan	NEWA
AP		100MG/5ML (20MG/ML)	N90016	002	Jan 28, 2009	Mar	NEWA
AP		100MG/5ML (20MG/ML)	N90016	002	Jan 28, 2009	Jan	NEWA

ISOSORBIDE DINITRATE

	TABLET; SUBLINGUAL						
	ISOSORBIDE DINITRATE						
	@ SANDOZ	2.5MG	N86225	001	Feb 19, 1988	Mar	DISC
	@	5MG	N86222	001	Feb 19, 1988	Mar	DISC

KETOCONAZOLE

	GEL; TOPICAL						
	XOLEGEL						
+	STIEFEL LABS INC	2%	N21946	001	Jul 28, 2006	Jan	CAHN

KETOPROFEN

	CAPSULE; ORAL						
	KETOPROFEN						
	@ SANDOZ	50MG	N74024	001	Dec 29, 1995	Mar	DISC
	@	75MG	N74024	002	Dec 29, 1995	Mar	DISC

LAMOTRIGINE

	TABLET; ORAL						
	LAMOTRIGINE						
AB	APOTEX INC	25MG	N78625	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78625	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78625	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78625	004	Jan 27, 2009	Jan	NEWA
AB	AUROBINDO PHARMA	25MG	N78956	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78956	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78956	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78956	004	Jan 27, 2009	Jan	NEWA
AB	CADISTA PHARMS	25MG	N79132	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N79132	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N79132	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N79132	004	Jan 27, 2009	Jan	NEWA
AB	DR REDDYS LABS LTD	25MG	N76708	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N76708	002	Jan 27, 2009	Jan	NEWA

TABLET; ORAL

LAMOTRIGINE

AB	DR REDDYS LABS LTD	150MG	N76708 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N76708 004	Jan 27, 2009	Jan	NEWA
AB	GENPHARM ULC	25MG	N77428 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77428 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77428 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77428 004	Jan 27, 2009	Jan	NEWA
AB	MATRIX LABS LTD	25MG	N78443 001	Feb 11, 2009	Jan	NEWA
AB		100MG	N78443 002	Feb 11, 2009	Jan	NEWA
AB		150MG	N78443 003	Feb 11, 2009	Jan	NEWA
AB		200MG	N78443 004	Feb 11, 2009	Jan	NEWA
AB	MYLAN	25MG	N77420 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77420 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77420 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77420 004	Jan 27, 2009	Jan	NEWA
AB	ROXANE	25MG	N77392 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77392 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77392 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77392 004	Jan 27, 2009	Jan	NEWA
AB	SANDOZ	25MG	N78645 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78645 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78645 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78645 004	Jan 27, 2009	Jan	NEWA
AB	TARO PHARM INDS	25MG	N78525 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78525 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78525 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78525 004	Jan 27, 2009	Jan	NEWA
AB	TORRENT PHARMS	25MG	N78947 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78947 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78947 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78947 004	Jan 27, 2009	Jan	NEWA
AB	UPSHER SMITH	25MG	N78310 001	Feb 04, 2009	Jan	NEWA
AB		100MG	N78310 002	Feb 04, 2009	Jan	NEWA
AB		150MG	N78310 003	Feb 04, 2009	Jan	NEWA
AB		200MG	N78310 004	Feb 04, 2009	Jan	NEWA
AB	WOCKHARDT	25MG	N78982 001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78982 002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78982 003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78982 004	Jan 27, 2009	Jan	NEWA
AB	ZYDUS PHARMS USA	25MG	N77633 001	Jan 27, 2009	Jan	NEWA
		50MG	N77633 002	Jan 27, 2009	Jan	NEWA
AB		100MG	N77633 003	Jan 27, 2009	Jan	NEWA
AB		150MG	N77633 004	Jan 27, 2009	Jan	NEWA
AB		200MG	N77633 005	Jan 27, 2009	Jan	NEWA
		250MG	N77633 006	Jan 27, 2009	Jan	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	5MG	N79099 001	Feb 19, 2009	Feb	NEWA
AB		25MG	N79099 002	Feb 19, 2009	Feb	NEWA
AB	TARO	5MG	N79204 001	Feb 04, 2009	Jan	NEWA
AB		25MG	N79204 002	Feb 04, 2009	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

	SMITHKLINE BEECHAM	25MG	N22115 001	May 29, 2009	May	NEWA
		50MG	N22115 002	May 29, 2009	May	NEWA

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

	SMITHKLINE BEECHAM	100MG	N22115 003	May 29, 2009	May	NEWA
+		200MG	N22115 004	May 29, 2009	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

LAMICTAL ODT

	SMITHKLINE BEECHAM	25MG	N22251 001	May 08, 2009	May	NEWA
		50MG	N22251 002	May 08, 2009	May	NEWA
		100MG	N22251 003	May 08, 2009	May	NEWA
+		200MG	N22251 004	May 08, 2009	May	NEWA

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL

PREVACID

@	TAKEDA PHARMS NA	15MG/PACKET	N21281 001	May 03, 2001	May	DISC
@		30MG/PACKET	N21281 002	May 03, 2001	May	DISC

LEUCOVORIN CALCIUM

TABLET; ORAL

LEUCOVORIN CALCIUM

>A>	@	COREPHARMA	EQ 5MG BASE	N74544 001	Aug 28, 1997	Jun	CAHN
>A>	@		EQ 25MG BASE	N74544 002	Aug 28, 1997	Jun	CAHN
>D>	@	PAR PHARM	EQ 5MG BASE	N74544 001	Aug 28, 1997	Jun	CAHN
>D>	@		EQ 25MG BASE	N74544 002	Aug 28, 1997	Jun	CAHN
>D>	AB	ROXANE	EQ 10MG BASE	N72734 001	Feb 22, 1993	Jun	CTEC
>A>			EQ 10MG BASE	N72734 001	Feb 22, 1993	Jun	CTEC
	@	XANODYNE PHARM	EQ 5MG BASE	N18459 001	Jan 30, 1986	May	DISC
>D>	AB		EQ 10MG BASE	N71962 001	Nov 19, 1987	Jun	DISC
>A>	@		EQ 10MG BASE	N71962 001	Nov 19, 1987	Jun	DISC

LEUPROLIDE ACETATE

>D>		IMPLANT; IMPLANTATION					
>D>		VIADUR					
>D>	+	JOHNSON AND JOHNSON	EQ 65MG BASE	N21088 001	Mar 03, 2000	Jun	DISC
>A>	@	ORTHO MCNEIL JANSSEN	EQ 65MG BASE	N21088 001	Mar 03, 2000	Jun	DISC

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

AP	SUN PHARMA GLOBAL	1MG/0.2ML	N78885 001	Mar 09, 2009	Feb	NEWA
----	-------------------	-----------	------------	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	DEY	EQ 0.25% BASE	N78309 001	Mar 20, 2009	Mar	NEWA	
AN	+	XOPENEX					
	+	SEPRACOR	EQ 0.25% BASE	N20837 004	Jul 18, 2003	Mar	CFTG

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

AA	SILARX	100MG/ML	N90263 001	Apr 03, 2009	Mar	NEWA
AA	TARO	100MG/ML	N78774 001	Feb 10, 2009	Jan	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	APOTEX INC	250MG	N78869 001	Mar 13, 2009	Mar	NEWA
AB		500MG	N78869 002	Mar 13, 2009	Mar	NEWA
AB		750MG	N78869 003	Mar 13, 2009	Mar	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	APOTEX INC	1GM	N78869 004	Mar 13, 2009	Mar	NEWA
AB	CIPLA LTD	250MG	N77319 001	Mar 20, 2009	Mar	NEWA
AB		500MG	N77319 002	Mar 20, 2009	Mar	NEWA
AB		750MG	N77319 003	Mar 20, 2009	Mar	NEWA
AB	GENPHARM ULC	250MG	N78731 001	Feb 10, 2009	Jan	NEWA
AB		500MG	N78731 002	Feb 10, 2009	Jan	NEWA
AB		750MG	N78731 003	Feb 10, 2009	Jan	NEWA
AB		1GM	N78731 004	Feb 10, 2009	Jan	NEWA
AB	SOLCO HLTHCARE	250MG	N78106 001	Feb 10, 2009	Jan	NEWA
AB		500MG	N78106 002	Feb 10, 2009	Jan	NEWA
AB		750MG	N78106 003	Feb 10, 2009	Jan	NEWA
AB		1GM	N78106 004	Feb 10, 2009	Jan	NEWA
AB	WATSON LABS FLORIDA	250MG	N77408 001	Mar 02, 2009	Feb	NEWA
AB		500MG	N77408 002	Mar 02, 2009	Feb	NEWA
AB		750MG	N77408 003	Mar 02, 2009	Feb	NEWA
AB	ZYDUS PHARMS USA INC	250MG	N78918 001	Apr 29, 2009	Apr	NEWA
AB		1GM	N78918 002	Apr 29, 2009	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

	UCB INC	500MG	N22285 001	Sep 12, 2008	Feb	CRLD
+		750MG	N22285 002	Feb 12, 2009	Feb	NEWA

LEVOFLOXACIN

TABLET; ORAL

LEVAQUIN

>D>	AB	ORTHO MCNEIL JANSSEN	250MG	N20634 001	Dec 20, 1996	Jun	CTEC
>A>			250MG	N20634 001	Dec 20, 1996	Jun	CTEC
	AB		250MG	N20634 001	Dec 20, 1996	Apr	CFTG
>D>	AB		500MG	N20634 002	Dec 20, 1996	Jun	CTEC
>A>			500MG	N20634 002	Dec 20, 1996	Jun	CTEC
	AB		500MG	N20634 002	Dec 20, 1996	Apr	CFTG
>D>	AB	+	750MG	N20634 003	Sep 08, 2000	Jun	CTEC
>A>		+	750MG	N20634 003	Sep 08, 2000	Jun	CTEC
	AB	+	750MG	N20634 003	Sep 08, 2000	Apr	CFTG

LEVONORGESTREL

TABLET; ORAL

>A>		LEVONORGESTREL					
>A>	AB	WATSON LABS	0.75MG	N78666 001	Jun 24, 2009	Jun	NEWA

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVOTHYROXINE SODIUM

AB2, AB3	MERCK KGAA	0.025MG	N76752 001	Jun 16, 2005	Apr	CAHN
AB2, AB3		0.05MG	N76752 002	Jun 16, 2005	Apr	CAHN
AB2, AB3		0.075MG	N76752 003	Jun 16, 2005	Apr	CAHN
AB2, AB3		0.088MG	N76752 004	Jun 16, 2005	Apr	CAHN
AB2, AB3		0.1MG	N76752 005	Jun 16, 2005	Apr	CAHN
AB2, AB3		0.112MG	N76752 006	Jun 16, 2005	Apr	CAHN

TABLET; ORAL

LEVOTHYROXINE SODIUM

AB2, AB3	MERCK KGAA	0.125MG	N76752 007	Jun 16, 2005	Apr	CAHN
AB2, AB3		0.15MG	N76752 008	Jun 16, 2005	Apr	CAHN
AB2, AB3		0.175MG	N76752 009	Jun 16, 2005	Apr	CAHN
AB2, AB3		0.2MG	N76752 010	Jun 16, 2005	Apr	CAHN
AB2, AB3		0.3MG	N76752 011	Jun 16, 2005	Apr	CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

	@ HOSPIRA	10%	N88367 001	Jul 31, 1984	Apr	DISC
XYLOCAINE						
AP	+ APP PHARMS	2%	N06488 002		Apr	CMFD
XYLOCAINE DENTAL						
AP	+ DENTSPLY PHARM	2%	N21380 001		Apr	CTNA
SYSTEM; INTRADERMAL						
ZINGO						
	@ ANESIVA	0.5MG	N22114 001	Aug 16, 2007	May	DISC

LINDANE

LOTION; TOPICAL

LINDANE

	@ OLTA PHARMS	1%	N87313 001		Apr	CAHN
--	---------------	----	------------	--	-----	------

SHAMPOO; TOPICAL

LINDANE

AT	+ OLTA PHARMS	1%	N87266 001		Jan	CAHN
----	---------------	----	------------	--	-----	------

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

AB	KING PHARMS	EQ 0.005MG BASE	N10379 001		Mar	CFTG
AB		EQ 0.025MG BASE	N10379 002		Mar	CTEC
AB	+	EQ 0.05MG BASE	N10379 003		Mar	CTEC

LIOTHYRONINE SODIUM

AB	COASTAL PHARMS	EQ 0.005MG BASE	N90097 001	Mar 20, 2009	Mar	NEWA	
AB		EQ 0.025MG BASE	N90097 002	Mar 20, 2009	Mar	NEWA	
AB		EQ 0.05MG BASE	N90097 003	Mar 20, 2009	Mar	NEWA	
>A>	AB	MYLAN	EQ 0.005MG BASE	N90326 001	Jul 14, 2009	Jun	NEWA
>A>	AB		EQ 0.025MG BASE	N90326 002	Jul 14, 2009	Jun	NEWA
>A>	AB		EQ 0.05MG BASE	N90326 003	Jul 14, 2009	Jun	NEWA

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB	GLENMARK GENERICS	150MG	N79139 001	Feb 03, 2009	Jan	NEWA
AB		300MG	N79139 002	Feb 03, 2009	Jan	NEWA
AB		600MG	N79139 003	Feb 03, 2009	Jan	NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

	@ SANDOZ	2MG	N72993 001	Aug 28, 1992	Mar	DISC
--	----------	-----	------------	--------------	-----	------

LORAZEPAM

	CONCENTRATE; ORAL						
	LORAZEPAM						
AA	PADDOCK LABS	2MG/ML	N79244 001	Apr 28, 2009	Apr	NEWA	
	LORAZEPAM INTENSOL						
AA	+ ROXANE	2MG/ML	N72755 001	Jun 28, 1991	Apr	CFTG	
	SOLUTION; ORAL						
	LORAZEPAM						
	@ ROXANE	0.5MG/5ML	N74648 001	Mar 18, 1997	Mar	DISC	

MALATHION

	LOTION; TOPICAL						
	MALATHION						
AT	SYNERX PHARMA	0.5%	N78743 001	Mar 06, 2009	Feb	NEWA	
	OVIDE						
AT	+ TARO PHARMS NORTH	0.5%	N18613 001	Aug 02, 1982	Feb	CFTG	

MECHLORETHAMINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	MUSTARGEN						
	+ LUNDBECK INC	10MG/VIAL	N06695 001		Apr	CAHN	

MECLIZINE HYDROCHLORIDE

	TABLET; ORAL						
	ANTIVERT						
AA	+ PFIZER	12.5MG	N10721 006		Jan	CAHN	
AA	+	25MG	N10721 004		Jan	CAHN	
AA	+	50MG	N10721 001	Jan 20, 1982	Jan	CAHN	

MECLOFENAMATE SODIUM

	CAPSULE; ORAL						
	MECLOFENAMATE SODIUM						
	@ SANDOZ	EQ 50MG BASE	N72262 001	Nov 29, 1988	Mar	DISC	
	@	EQ 100MG BASE	N72263 001	Nov 29, 1988	Mar	DISC	

MEDROXYPROGESTERONE ACETATE

	INJECTABLE; INJECTION						
	MEDROXYPROGESTERONE ACETATE						
AB	SANDOZ	150MG/ML	N78711 001	May 20, 2009	May	NEWA	

MELOXICAM

	TABLET; ORAL						
	MELOXICAM						
AB	BEJING YABAO	7.5MG	N77933 001	Jul 19, 2006	Apr	CAHN	
AB		15MG	N77933 002	Jul 19, 2006	Apr	CAHN	
AB	STRIDES ARCOLAB LTD	7.5MG	N77928 001	May 13, 2009	May	NEWA	
AB		15MG	N77928 002	May 13, 2009	May	NEWA	

MELPHALAN HYDROCHLORIDE

	INJECTABLE; INJECTION						
	ALKERAN						
>D>	+ GLAXOSMITHKLINE	EQ 50MG BASE/VIAL	N20207 001	Nov 18, 1992	Jun	CFTG	
>A>	AP +	EQ 50MG BASE/VIAL	N20207 001	Nov 18, 1992	Jun	CFTG	
>A>	MELPHALAN HYDROCHLORIDE						
>A>	AP SYNERX	EQ 50MG BASE/VIAL	N90270 001	Jun 09, 2009	Jun	NEWA	

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

>A>	AA	MIKART	50MG	N40893 001	Jun 24, 2009	Jun	NEWA
>A>			75MG	N40893 002	Jun 24, 2009	Jun	NEWA
>A>	AA		100MG	N40893 003	Jun 24, 2009	Jun	NEWA
>A>			150MG	N40893 004	Jun 24, 2009	Jun	NEWA

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

>D>	AP	ABRAXIS BIOSCIENCE	1%	N89407 001	Dec 01, 1986	Jun	CAHN
>D>	AP		2%	N89410 001	Dec 01, 1986	Jun	CAHN
>A>	AP	APP PHARMS	1%	N89407 001	Dec 01, 1986	Jun	CAHN
>A>	AP		2%	N89410 001	Dec 01, 1986	Jun	CAHN

POLOCAINE-MPF

>D>	AP	ABRAXIS BIOSCIENCE	1%	N89406 001	Dec 01, 1986	Jun	CAHN
>D>	AP		1.5%	N89408 001	Dec 01, 1986	Jun	CAHN
>D>	AP		2%	N89409 001	Dec 01, 1986	Jun	CAHN
>A>	AP	APP PHARMS	1%	N89406 001	Dec 01, 1986	Jun	CAHN
>A>	AP		1.5%	N89408 001	Dec 01, 1986	Jun	CAHN
>A>	AP		2%	N89409 001	Dec 01, 1986	Jun	CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

AA		ALEMBIC LTD	200MG	N90122 001	Feb 18, 2009	Feb	NEWA
AA			400MG	N90122 002	Feb 18, 2009	Feb	NEWA
		@ IVC INDS	400MG	N84153 001		Apr	CAHN

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+		STIEFEL LABS INC	2%;0.01%	N20922 001	Dec 10, 1999	Jan	CAHN
---	--	------------------	----------	------------	--------------	-----	------

MESALAMINE

TABLET, DELAYED RELEASE; ORAL

ASACOL

+		PROCTER AND GAMBLE	800MG	N21830 001	May 29, 2008	May	CTNA
---	--	--------------------	-------	------------	--------------	-----	------

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/50M-21

@		WATSON LABS	0.05MG;1MG	N71539 001	Apr 12, 1988	Apr	DISC
---	--	-------------	------------	------------	--------------	-----	------

NORETHINDRONE AND MESTRANOL

@		WATSON LABS	0.05MG;1MG	N70758 001	Jul 01, 1988	Apr	DISC
---	--	-------------	------------	------------	--------------	-----	------

NORINYL 1+50 21-DAY

@		WATSON LABS	0.05MG;1MG	N13625 002		Apr	DISC
---	--	-------------	------------	------------	--	-----	------

TABLET; ORAL-28

NORETHIN 1/50M-28

@		WATSON LABS	0.05MG;1MG	N71540 001	Apr 12, 1988	Apr	DISC
---	--	-------------	------------	------------	--------------	-----	------

NORETHINDRONE AND MESTRANOL

@		WATSON LABS	0.05MG;1MG	N70759 001	Jul 01, 1988	Apr	DISC
---	--	-------------	------------	------------	--------------	-----	------

NORINYL 1+50 28-DAY

+		WATSON LABS	0.05MG;1MG	N16659 001		Apr	CRLD
---	--	-------------	------------	------------	--	-----	------

TABLET; ORAL-28

ORTHO-NOVUM 1/50 28

@ ORTHO MCNEIL JANSSEN 0.05MG;1MG

N16709 001

Apr DISC

METAPROTERENOL SULFATE

SOLUTION; INHALATION

ALUPENT

@ BOEHRINGER INGELHEIM 0.4%

N18761 002 Oct 10, 1986 Feb DISC

@ 0.6%

N18761 001 Jun 30, 1983 Feb DISC

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB ALVOGEN 500MG

N76033 001 Jan 24, 2002 Jan CAHN

AB 850MG

N76033 002 Jan 24, 2002 Jan CAHN

AB 1GM

N76033 003 Jan 24, 2002 Jan CAHN

AB PROVIDENT PHARM 500MG

N77853 001 Jul 28, 2006 Apr CAHN

AB 850MG

N77853 002 Jul 28, 2006 Apr CAHN

AB 1GM

N77853 003 Jul 28, 2006 Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

@ SANDOZ 500MG

N76223 001 Dec 14, 2004 Mar DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

TAKEDA GLOBAL 1GM;EQ 15MG BASE

N22024 001 May 12, 2009 May NEWA

+ 1GM;EQ 30MG BASE

N22024 002 May 12, 2009 May NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

+ LUNDBECK INC 5MG

N05378 002

Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

DESOXYN

@ LUNDBECK INC 5MG

N05378 004

Apr CAHN

@ 10MG

N05378 003

Apr CAHN

@ 15MG

N05378 005

Apr CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB GENPHARM 10MG

N40350 002 Mar 29, 2000 May CRLD

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

@ SOLCO HLTHCARE 500MG

N86989 001

Jan CAHN

@ 750MG

N86988 001

Jan CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP EBEWE PARENTA EQ 50MG BASE/2ML (EQ 25MG
BASE/ML)

N90039 001 Mar 31, 2009 Mar NEWA

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	EBEWE PARENTA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	N90039 002	Mar 31, 2009	Mar	NEWA
AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N90029 001	Mar 31, 2009	Mar	NEWA

METHYLCLOTHIAZIDE

TABLET; ORAL

ENDURON

	ABBOTT	2.5MG	N12524 001		Mar	CTEC
--	--------	-------	------------	--	-----	------

METHYLCLOTHIAZIDE

	@ SANDOZ	2.5MG	N89835 001	Aug 18, 1988	Mar	DISC
--	----------	-------	------------	--------------	-----	------

	@	5MG	N89837 001	Aug 18, 1988	Mar	DISC
--	---	-----	------------	--------------	-----	------

METHYLDOPA

TABLET; ORAL

METHYLDOPA

	@ SANDOZ	125MG	N71700 001	Mar 02, 1988	Mar	DISC
--	----------	-------	------------	--------------	-----	------

	@	250MG	N18934 001	Jun 29, 1984	Mar	DISC
--	---	-------	------------	--------------	-----	------

	@	500MG	N18934 002	Jun 29, 1984	Mar	DISC
--	---	-------	------------	--------------	-----	------

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

>D>	PHARMACIA AND UPJOHN	24MG	N11153 005		Jun	DISC
-----	----------------------	------	------------	--	-----	------

>A>	@	24MG	N11153 005		Jun	DISC
-----	---	------	------------	--	-----	------

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AB	SANDOZ	40MG/ML	N40719 001	Jan 29, 2009	Jan	NEWA
----	--------	---------	------------	--------------	-----	------

AB		40MG/ML	N40794 001	Mar 05, 2009	Feb	NEWA
----	--	---------	------------	--------------	-----	------

AB		80MG/ML	N40719 002	Jan 29, 2009	Jan	NEWA
----	--	---------	------------	--------------	-----	------

AB		80MG/ML	N40794 002	Mar 05, 2009	Feb	NEWA
----	--	---------	------------	--------------	-----	------

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	VISTAPHARM	EQ 5MG BASE/5ML	N75051 001	Jan 26, 2001	Mar	CMFD
----	------------	-----------------	------------	--------------	-----	------

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

	@ SANDOZ	EQ 5MG BASE	N74478 001	Oct 05, 1995	Mar	DISC
--	----------	-------------	------------	--------------	-----	------

	@	EQ 10MG BASE	N72215 001	Jan 30, 1990	Mar	DISC
--	---	--------------	------------	--------------	-----	------

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

>A>	AB	MUTUAL PHARM	25MG	N73654 002	Jul 15, 2009	Jun	NEWA
-----	----	--------------	------	------------	--------------	-----	------

	@	SOLCO HLTHCARE	50MG	N74453 001	Apr 27, 1995	Jan	CAHN
--	---	----------------	------	------------	--------------	-----	------

	@		100MG	N74453 002	Apr 27, 1995	Jan	CAHN
--	---	--	-------	------------	--------------	-----	------

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

>A>	AB	ALEMBIC LTD	375MG	N79065 001	Jun 23, 2009	Jun	NEWA
-----	----	-------------	-------	------------	--------------	-----	------

TABLET; ORAL

METRONIDAZOLE

AB	ALEMBIC LTD	250MG	N79067 001	Mar 13, 2009	Mar	NEWA
AB		500MG	N79067 002	Mar 13, 2009	Mar	NEWA
	@ SANDOZ	250MG	N18740 001	Oct 22, 1982	Mar	DISC
	@	500MG	N18740 002	Oct 22, 1982	Mar	DISC
>D>	AB	TEVA	N70035 001	Dec 20, 1984	Jun	CAHN
>A>	AB	WATSON LABS	N70035 001	Dec 20, 1984	Jun	CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

	@ SANDOZ	150MG	N74450 001	May 16, 1996	Mar	DISC
	@	200MG	N74450 002	May 16, 1996	Mar	DISC
	@	250MG	N74450 003	May 16, 1996	Mar	DISC

MICONAZOLE NITRATE

>D>	CREAM; TOPICAL					
>D>	MONISTAT-DERM					
>D>	+ ORTHONEUTROGENA	2%	N17494 001		Jun	DISC
>A>	@	2%	N17494 001		Jun	DISC

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

	+ STIEFEL LABS INC	0.25%;81.35%;15%	N21026 001	Feb 16, 2006	Jan	CAHN
--	--------------------	------------------	------------	--------------	-----	------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

	CYPRESS BIOSCIENCE	12.5MG	N22256 001	Jan 14, 2009	Jan	NEWA
		25MG	N22256 002	Jan 14, 2009	Jan	NEWA
		50MG	N22256 003	Jan 14, 2009	Jan	NEWA
	+	100MG	N22256 004	Jan 14, 2009	Jan	NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

>D>	AP	BEDFORD	EQ 1MG BASE/ML	N75660 001	May 28, 2002	Jun	CRLD
>A>	AP	+	EQ 1MG BASE/ML	N75660 001	May 28, 2002	Jun	CRLD

MINOCYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

MINOCIN

	+ TRIAX PHARMS LLC	EQ 100MG BASE/VIAL	N50444 001		May	CMFD
--	--------------------	--------------------	------------	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	BARR	EQ 45MG BASE	N65485 001	Mar 17, 2009	Mar	NEWA
AB		EQ 90MG BASE	N65485 002	Mar 17, 2009	Mar	NEWA
AB		EQ 135MG BASE	N65485 003	Mar 17, 2009	Mar	NEWA
AB	IMPAX LABS INC	EQ 45MG BASE	N90024 001	Feb 03, 2009	Jan	NEWA
AB		EQ 90MG BASE	N90024 002	Feb 03, 2009	Jan	NEWA
AB		EQ 135MG BASE	N90024 003	Feb 03, 2009	Jan	NEWA
	SOLODYN					
AB	MEDICIS	EQ 45MG BASE	N50808 001	May 08, 2006	Jan	CFTG
AB		EQ 90MG BASE	N50808 002	May 08, 2006	Jan	CFTG

TABLET, EXTENDED RELEASE; ORAL

SOLODYN

AB	+	MEDICIS	EQ 135MG BASE	N50808 003	May 08, 2006	Jan	CFTG
----	---	---------	---------------	------------	--------------	-----	------

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP		GENERAMEDIX	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N78980 001	Apr 13, 2009	Mar	NEWA
AP			EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	N78980 002	Apr 13, 2009	Mar	NEWA

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

	+	EBEWE PARENTA	EQ 2MG BASE/ML	N78562 001	Apr 30, 2009	Apr	NEWA
--	---	---------------	----------------	------------	--------------	-----	------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

	+	ACTAVIS ELIZABETH	10MG	N20616 008	Apr 20, 2007	Feb	CRLD
	+		80MG	N20616 006	Oct 27, 2006	Feb	CRLD

INJECTABLE; INJECTION

ASTRAMORPH PF

>D>	AP	ABRAXIS BIOSCIENCE	0.5MG/ML	N71050 001	Oct 07, 1986	Jun	CAHN
>D>	AP		0.5MG/ML	N71051 001	Oct 07, 1986	Jun	CAHN
>D>	AP		1MG/ML	N71052 001	Oct 07, 1986	Jun	CAHN
>D>	AP		1MG/ML	N71053 001	Oct 07, 1986	Jun	CAHN
>A>	AP	APP PHARMS	0.5MG/ML	N71050 001	Oct 07, 1986	Jun	CAHN
>A>	AP		0.5MG/ML	N71051 001	Oct 07, 1986	Jun	CAHN
>A>	AP		1MG/ML	N71052 001	Oct 07, 1986	Jun	CAHN
>A>	AP		1MG/ML	N71053 001	Oct 07, 1986	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

	@	AB GENERICS	15MG	N74862 001	Jul 07, 1998	Apr	DISC
	@		30MG	N74862 002	Jul 07, 1998	Apr	DISC
	@		60MG	N74862 003	Jul 07, 1998	Apr	DISC
	@		100MG	N74769 001	Jul 02, 1998	Apr	DISC
	@		200MG	N74769 002	Jul 02, 1998	Apr	DISC

MOXIFLOXACIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

>A>	+	BAYER HLTHCARE	160MG/100ML	N21277 001	Nov 30, 2001	Jun	CAHN
>D>	+	BAYER PHARMS	160MG/100ML	N21277 001	Nov 30, 2001	Jun	CAHN

TABLET; ORAL

AVELOX

>A>	+	BAYER HLTHCARE	EQ 400MG BASE	N21085 001	Dec 10, 1999	Jun	CAHN
>D>	+	BAYER PHARMS	EQ 400MG BASE	N21085 001	Dec 10, 1999	Jun	CAHN

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE INC	250MG	N90253 001	May 04, 2009	Apr	NEWA
AB		APOTEX CORP	250MG	N90419 001	Apr 22, 2009	Apr	NEWA
AB		MYLAN	250MG	N65520 001	May 04, 2009	Apr	NEWA

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

AB	TEVA PHARMS	250MG	N65491 001	May 06, 2009	Apr	NEWA
AB	ZYDUS PHARMS USA INC	250MG	N65433 001	May 04, 2009	Apr	NEWA

TABLET; ORAL

MYCOPHENOLATE MOFETIL

AB	ACCORD HLTHCARE	500MG	N65416 001	May 04, 2009	Apr	NEWA
AB	APOTEX	500MG	N90499 001	Apr 22, 2009	Apr	NEWA
AB	MYLAN	500MG	N65521 001	May 04, 2009	Apr	NEWA
AB	TEVA PHARMS	500MG	N65457 001	May 04, 2009	Apr	NEWA
AB	ZYDUS PHARMS USA INC	500MG	N65477 001	May 04, 2009	Apr	NEWA

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	ACTAVIS ELIZABETH	500MG	N79093 001	Feb 27, 2009	Feb	NEWA
AB		750MG	N79093 002	Feb 27, 2009	Feb	NEWA
	@ SANDOZ	500MG	N75590 001	Feb 25, 2002	Mar	DISC
	@	750MG	N75590 002	Feb 25, 2002	Mar	DISC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

	MALLINCKRODT	100MG	N76264 003	Mar 22, 2002	May	CRLD
--	--------------	-------	------------	--------------	-----	------

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

+	STAT TRADE	EQ 375MG BASE	N20353 001	Jan 05, 1996	Mar	CTEC
+		EQ 500MG BASE	N20353 002	Jan 05, 1996	Mar	CTEC

NAPROXEN SODIUM

@	WATSON LABS FLORIDA	EQ 375MG BASE	N75416 002	Apr 23, 2003	Mar	DISC
@		EQ 500MG BASE	N75416 001	Aug 27, 2002	Mar	DISC

NIFEDIPINE

CAPSULE; ORAL

PROCARDIA

AB	+	PFIZER	10MG	N18482 001		Apr	CRLD
		@	20MG	N18482 002	Jul 24, 1986	Apr	DISC

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

>A>	AB1	BAYER HLTHCARE	30MG	N20198 001	Apr 21, 1993	Jun	CAHN
>A>	AB1	+	60MG	N20198 002	Apr 21, 1993	Jun	CAHN
>A>	AB1	+	90MG	N20198 003	Apr 21, 1993	Jun	CAHN
>D>	AB1	BAYER PHARMS	30MG	N20198 001	Apr 21, 1993	Jun	CAHN
>D>	AB1	+	60MG	N20198 002	Apr 21, 1993	Jun	CAHN
>D>	AB1	+	90MG	N20198 003	Apr 21, 1993	Jun	CAHN

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

AB	+	BARR	30MG	N77811 001	May 02, 2007	Mar	CRLD
		NIMOTOP					
	@	BAYER PHARMS	30MG	N18869 001	Dec 28, 1988	Feb	DISC

NITISINONE

CAPSULE; ORAL

ORFADIN

	RARE DIS	2MG	N21232 001	Jan 18, 2002	Mar	CAHN
		5MG	N21232 002	Jan 18, 2002	Mar	CAHN
+		10MG	N21232 003	Jan 18, 2002	Mar	CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

	@ SANDOZ	25MG	N74336 001	Jan 25, 1995	Mar	DISC
	@	50MG	N74336 002	Jan 25, 1995	Mar	DISC
	@	100MG	N74336 003	Jan 25, 1995	Mar	DISC

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

AT	FDC LTD	0.3%	N78559 001	Feb 25, 2009	Feb	NEWA
----	---------	------	------------	--------------	-----	------

TABLET; ORAL

FLOXIN

	@ ORTHO MCNEIL JANSSEN	200MG	N19735 001	Dec 28, 1990	Mar	DISC
	@	300MG	N19735 002	Dec 28, 1990	Mar	DISC
	@	400MG	N19735 003	Dec 28, 1990	Mar	DISC

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

>D>	+	ALAVEN PHARM	250MG	N19715 001	Jul 31, 1990	Jun	CAHN
	+		250MG	N19715 001	Jul 31, 1990	Apr	CAHN
>A>	+	UCB INC	250MG	N19715 001	Jul 31, 1990	Jun	CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	DR REDDYS LABS	40MG	N78490 001	Apr 17, 2009	Mar	NEWA
AB	DR REDDYS LABS LTD	10MG	N78693 001	Mar 16, 2009	Mar	NEWA
AB		20MG	N78693 002	Mar 16, 2009	Mar	NEWA
AB	KREMERS URBAN DEV	40MG	N75410 003	Jan 23, 2009	Jan	NEWA

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE MAGNESIUM

	DR REDDYS LABS LTD	20MG	N78878 001	Jun 05, 2009	May	NEWA
--	--------------------	------	------------	--------------	-----	------

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

AP	BEDFORD LABS	EQ 0.64MG BASE/ML	N78291 001	Apr 13, 2009	Mar	NEWA
----	--------------	-------------------	------------	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

	@ WATSON LABS	EQ 250MG BASE/VIAL	N62856 001	Oct 26, 1988	Apr	DISC
	@	EQ 500MG BASE/VIAL	N62856 002	Oct 26, 1988	Apr	DISC
	@	EQ 1GM BASE/VIAL	N62856 003	Oct 26, 1988	Apr	DISC

INJECTABLE; INJECTION

OXACILLIN SODIUM

@ WATSON LABS

EQ 2GM BASE/VIAL

N62856 004 Oct 26, 1988 Apr DISC

@

EQ 4GM BASE/VIAL

N62856 005 Oct 26, 1988 Apr DISC

OXAPROZIN

TABLET; ORAL

OXAPROZIN

@ SANDOZ

600MG

N75850 001 Apr 27, 2001 Mar DISC

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

>A>

>A> AB

RANBAXY

300MG/5ML

N78734 001 Jun 26, 2009 Jun NEWA

TRILEPTAL

>D>

+ NOVARTIS

300MG/5ML

N21285 001 May 25, 2001 Jun CFTG

>A> AB

+

300MG/5ML

N21285 001 May 25, 2001 Jun CFTG

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

>D>

+ PARKE DAVIS

400MG

N87863 001 May 24, 1983 Jun CAHN

>A>

+ WARNER CHILCOTT

400MG

N87863 001 May 24, 1983 Jun CAHN

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

+ WATSON LABS

10%(100MG/PACKET)

N22204 001 Jan 27, 2009 Mar CTNA

OXYBUTYNIN CHLORIDE

+ WATSON LABS

10%(100MG/PACKET)

N22204 001 Jan 27, 2009 Jan NEWA

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYIN CHLORIDE

AB

OSMOTICA PHARM

5MG

N78503 001 Feb 04, 2009 Jan NEWA

AB

10MG

N78503 002 Feb 04, 2009 Jan NEWA

AB

15MG

N78503 003 Feb 04, 2009 Jan NEWA

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB

SUN PHARM INDS INC

5MG

N90659 001 Apr 10, 2009 Mar NEWA

AB

15MG

N90659 002 Apr 10, 2009 Mar NEWA

AB

30MG

N90659 003 Apr 10, 2009 Mar NEWA

AB

VINTAGE PHARMS

5MG

N77712 003 Mar 02, 2009 Mar NEWA

ROXICODONE

AB

XANODYNE PHARMS

5MG

N21011 003 May 15, 2009 May NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP

GENERAMEDIX

30MG/VIAL

N78300 001 Mar 10, 2009 Feb NEWA

AP

90MG/VIAL

N78300 002 Mar 10, 2009 Feb NEWA

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE; ORAL

CREON

SOLVAY

30,000USP UNITS;6,000USP
UNITS;19,000USP UNITS

N20725 001 Apr 30, 2009 Apr NEWA

60,000USP UNITS;12,000USP
UNITS;38,000USP UNITS

N20725 002 Apr 30, 2009 Apr NEWA

+

120,000USP UNITS;24,000USP
UNITS;76,000USP UNITS

N20725 003 Apr 30, 2009 Apr NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

@ HOSPIRA

2MG/ML

N72321 001 Jan 19, 1989 Apr DISC

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB

KUDCO IRELAND

EQ 20MG BASE

N78281 001 Mar 17, 2009 Mar NEWA

AB

EQ 40MG BASE

N78281 002 Mar 17, 2009 Mar NEWA

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN-VK

AA

+ TEVA

EQ 250MG BASE/5ML

N60456 002

Apr CRLD

VEETIDS

@ APOTHECON

EQ 125MG BASE/5ML

N61410 001

Mar DISC

@

EQ 250MG BASE/5ML

N61410 002

Mar DISC

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

@ APP PHARMS

600MG/VIAL

N19887 002 Mar 22, 1996 May DISC

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

>A>

+ LUNDBECK INC

50MG/ML

N83246 001

Jun CAHN

>D>

+ OVATION PHARMS

50MG/ML

N83246 001

Jun CAHN

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

PHENDIMETRAZINE TARTRATE

@ SANDOZ

35MG

N85695 001

May DISC

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

AB

WOCKHARDT EU

125MG/5ML

N40420 001 Apr 19, 2002 Apr CAHN

PHENYTOIN SODIUM

CAPSULE; ORAL

PROMPT PHENYTOIN SODIUM

@ IVAX PHARMS

100MG PROMPT

N80259 001

Jan DISC

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB	LANNETT	7.5MG	N77220 002	May 06, 2009	Apr	NEWA
----	---------	-------	------------	--------------	-----	------

PINDOLOL

TABLET; ORAL

PINDOLOL

@ SANDOZ

5MG

N73608 001 Mar 29, 1993 Mar DISC

@

10MG

N73609 001 Mar 29, 1993 Mar DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

>A>	AA	BRECKENRIDGE PHARM	17GM/SCOOPFUL	N77736 001	May 26, 2006	Jun	CAHN
>D>	AA	GAVIS PHARMS	17GM/SCOOPFUL	N77736 001	May 26, 2006	Jun	CAHN
	AA		17GM/SCOOPFUL	N77736 001	May 26, 2006	Jan	CAHN
		@ TEVA PHARMS	17GM/SCOOPFUL	N77445 001	May 04, 2006	Jan	DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

PEG-3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

AA	NOVEL LABS INC	420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 1.2GM/BOT	N90019 001	May 27, 2009	May	NEWA
----	----------------	--	------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

GOLYTELY

+	BRAINTREE	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N19011 002	Jun 02, 1992	May	CTEC
AA	+	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	N19011 001	Jul 13, 1984	May	CFTG
	+	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	N19011 001	Jul 13, 1984	Mar	CTEC
AA	NOVEL LABS INC	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	N90231 001	Jun 01, 2009	May	NEWA
AA		240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N90186 001	Jun 01, 2009	May	NEWA

PEG 3350 AND ELECTROLYTES

FOR SUSPENSION; ORAL

CO-LAV

@ BOCA PHARMA

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT

N73428 001 Jan 28, 1992 Mar DISC

GO-EVAC

@ BOCA PHARMA

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

N73433 001 Apr 28, 1992 Mar DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

@ KV PHARM

8MEQ

N18238 001 Feb DISC

MICRO-K 10

@ KV PHARM

10MEQ

N18238 002 May 14, 1984 Feb DISC

POTASSIUM CHLORIDE

@ KV PHARM

10MEQ

N70980 001 Feb 17, 1987 Feb DISC

WATSON LABS FLORIDA

8MEQ

N77419 001 Jun 02, 2008 Feb CTEC

+

10MEQ

N77419 002 Jun 02, 2008 Feb CRLD

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

@ HOSPIRA 1.5MEQ/ML

N83345 001

Apr DISC

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB WATSON LABS FLORIDA 10MEQ

N75604 001 Apr 10, 2002 May CRLD

AB + 10MEQ

N75604 001 Apr 10, 2002 Jan CRLD

PRAZICQUANTEL

TABLET; ORAL

BILTRICIDE

>A> + BAYER HLTHCARE 600MG

N18714 001 Dec 29, 1982 Jun CAHN

>D> + BAYER PHARMS 600MG

N18714 001 Dec 29, 1982 Jun CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

@ SANDOZ EQ 1MG BASE

N72576 001 May 16, 1989 Mar DISC

@ EQ 2MG BASE

N72577 001 May 16, 1989 Mar DISC

@ EQ 5MG BASE

N72578 001 May 16, 1989 Mar DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA AMNEAL PHARMS EQ 15MG BASE/5ML

N78345 001 Mar 10, 2009 Feb NEWA

AA VINTAGE EQ 15MG BASE/5ML

N79010 001 May 26, 2009 May NEWA

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

@ BAUSCH AND LOMB EQ 0.11% PHOSPHATE

N40065 001 Jul 29, 1994 Apr DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

@ SANDOZ 10MG

N89983 001 Jan 12, 1989 Mar DISC

@ 50MG

N89984 001 Jan 12, 1989 Mar DISC

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN DENTAL

+ DENTSPLY PHARM 4%

N21382 001

Apr CTNA

PROGESTERONE

INJECTABLE; INJECTION

PROGESTERONE

>A> AP PHARMAFORCE 50MG/ML

N90845 001 Jun 22, 2009 Jun NEWA

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA SUN PHARM INDS INC 6.25MG/5ML

N40891 001 Mar 13, 2009 Mar NEWA

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

AB SANDOZ 12.5MG

N84176 002 May 22, 2009 May NEWA

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

>D>	AB	+	ABRAXIS BIOSCIENCE	10MG/ML	N19627 002	Jun 11, 1996	Jun	CAHN
>D>			@	10MG/ML	N19627 001	Oct 02, 1989	Jun	CAHN
>A>			@ APP PHARMS	10MG/ML	N19627 001	Oct 02, 1989	Jun	CAHN
>A>	AB	+		10MG/ML	N19627 002	Jun 11, 1996	Jun	CAHN

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DOLENE

	AA		HERITAGE PHARMS INC	65MG	N80530 001		Mar	CMFD
			PROPOXYPHENE HYDROCHLORIDE					
>A>	AA		VINTAGE PHARMS	65MG	N40908 001	Jul 17, 2009	Jun	NEWA

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

	AB		UPSHER SMITH	60MG	N78311 001	Mar 06, 2009	Feb	NEWA
	AB			80MG	N78311 002	Mar 06, 2009	Feb	NEWA
	AB			120MG	N78311 003	Mar 06, 2009	Feb	NEWA
	AB			160MG	N78311 004	Mar 06, 2009	Feb	NEWA

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

			@ SANDOZ	10MG	N70663 001	Jun 13, 1986	Mar	DISC
			@	20MG	N70664 001	Jun 13, 1986	Mar	DISC
			@	40MG	N70665 001	Jun 13, 1986	Mar	DISC
			@	60MG	N70666 001	Oct 10, 1986	Mar	DISC
			@	80MG	N70667 001	Jun 13, 1986	Mar	DISC

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

CORPHED

			@ SANDOZ	60MG;2.5MG	N88602 001	Apr 11, 1985	Mar	DISC
--	--	--	----------	------------	------------	--------------	-----	------

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

			+ SANDOZ	60MG;2.5MG	N88193 001	May 17, 1983	Mar	CTEC
--	--	--	----------	------------	------------	--------------	-----	------

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

>A>	AB		SUN PHARM INDS LTD	EQ 5MG BASE	N90800 001	Jun 18, 2009	Jun	NEWA
>A>	AB			EQ 10MG BASE	N90800 002	Jun 18, 2009	Jun	NEWA
>A>	AB			EQ 20MG BASE	N90800 003	Jun 18, 2009	Jun	NEWA
>A>	AB			EQ 40MG BASE	N90800 004	Jun 18, 2009	Jun	NEWA

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

	AB		RANBAXY	5MG	N78849 001	Mar 06, 2009	Feb	NEWA
	AB			10MG	N78849 002	Mar 06, 2009	Feb	NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

			@ BEDFORD	EQ 25MG BASE/ML	N74764 001	Nov 19, 2004	Apr	DISC
--	--	--	-----------	-----------------	------------	--------------	-----	------

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 15MG BASE/ML	N78312 001	Sep 02, 2008	Feb	CTNA
AA	DR REDDYS LABS LTD	EQ 15MG BASE/ML	N90102 001	May 26, 2009	May	NEWA
AA	WOCKHARDT	EQ 15MG BASE/ML	N79211 001	May 26, 2009	May	NEWA
AA		EQ 15MG BASE/ML	N79212 001	Feb 23, 2009	Feb	NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

>D>	CV THERAP	500MG	N21526 002	Jan 27, 2006	Jun	CAHN
>D>	+	1GM	N21526 001	Feb 12, 2007	Jun	CAHN
>A>	GILEAD	500MG	N21526 002	Jan 27, 2006	Jun	CAHN
>A>	+	1GM	N21526 001	Feb 12, 2007	Jun	CAHN

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

@ PROCTER AND GAMBLE

75MG

N20835 004 Apr 16, 2007 May DISC

RISPERIDONE

SOLUTION; ORAL

RISPERDAL

AA	+ ORTHO MCNEIL JANSSEN	1MG/ML	N20588 001	Jun 10, 1996	Jan	CFTG
----	------------------------	--------	------------	--------------	-----	------

RISPERIDONE

AA	TEVA	1MG/ML	N76440 001	Jan 30, 2009	Jan	NEWA
----	------	--------	------------	--------------	-----	------

TABLET; ORAL

RISPERIDONE

>A>	AB	ACTAVIS TOTOWA	0.25MG	N78071 001	Jun 17, 2009	Jun	NEWA
>A>	AB		0.5MG	N78071 002	Jun 17, 2009	Jun	NEWA
>A>	AB		1MG	N78071 003	Jun 17, 2009	Jun	NEWA
>A>	AB		2MG	N78071 004	Jun 17, 2009	Jun	NEWA
>A>	AB		3MG	N78071 005	Jun 17, 2009	Jun	NEWA
>A>	AB		4MG	N78071 006	Jun 17, 2009	Jun	NEWA
	AB	CADISTA PHARMS	0.25MG	N78828 001	Mar 23, 2009	Mar	NEWA
	AB		0.5MG	N78828 002	Mar 23, 2009	Mar	NEWA
	AB		1MG	N78828 003	Mar 23, 2009	Mar	NEWA
	AB		2MG	N78828 004	Mar 23, 2009	Mar	NEWA
	AB		3MG	N78828 005	Mar 23, 2009	Mar	NEWA
	AB		4MG	N78828 006	Mar 23, 2009	Mar	NEWA
	AB	WEST WARD PHARMS	0.25MG	N78740 001	May 29, 2009	May	NEWA
	AB		0.5MG	N78740 002	May 29, 2009	May	NEWA
	AB		1MG	N78740 003	May 29, 2009	May	NEWA
	AB		2MG	N78740 004	May 29, 2009	May	NEWA
	AB		3MG	N78740 005	May 29, 2009	May	NEWA
	AB		4MG	N78740 006	May 29, 2009	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

AB	ORTHO MCNEIL JANSSEN	0.5MG	N21444 001	Apr 02, 2003	Feb	CFTG
AB		2MG	N21444 003	Apr 02, 2003	Feb	CFTG
AB		3MG	N21444 004	Dec 23, 2004	Apr	CFTG
AB		4MG	N21444 005	Dec 23, 2004	Apr	CFTG

RISPERIDONE

AB	DR REDDYS LABS LTD	0.5MG	N77328 001	Feb 24, 2009	Feb	NEWA
AB		2MG	N77328 003	Feb 24, 2009	Feb	NEWA
>D>	KALI LABS	0.25MG	N77494 001	Apr 30, 2009	Jun	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

		KALI LABS	0.25MG	N77494 001	Apr 30, 2009	Apr	NEWA
>D>	AB		0.5MG	N77494 002	Apr 30, 2009	Jun	CAHN
	AB		0.5MG	N77494 002	Apr 30, 2009	Apr	NEWA
>D>	AB		2MG	N77494 004	Apr 30, 2009	Jun	CAHN
	AB		2MG	N77494 004	Apr 30, 2009	Apr	NEWA
>D>	AB		3MG	N77494 005	Apr 30, 2009	Jun	CAHN
	AB		3MG	N77494 005	Apr 30, 2009	Apr	NEWA
>D>	AB		4MG	N77494 006	Apr 30, 2009	Jun	CAHN
	AB		4MG	N77494 006	Apr 30, 2009	Apr	NEWA
>A>		PAR PHARM	0.25MG	N77494 001	Apr 30, 2009	Jun	CAHN
>A>	AB		0.5MG	N77494 002	Apr 30, 2009	Jun	CAHN
>A>	AB		2MG	N77494 004	Apr 30, 2009	Jun	CAHN
>A>	AB		3MG	N77494 005	Apr 30, 2009	Jun	CAHN
>A>	AB		4MG	N77494 006	Apr 30, 2009	Jun	CAHN
	AB	ZYDUS PHARMS USA	0.5MG	N78516 001	May 01, 2009	Apr	NEWA
	AB		2MG	N78516 003	May 01, 2009	Apr	NEWA

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HYDROCHLORIDE

	@	HOSPIRA	10MG/ML	N71618 001	Feb 28, 1991	Apr	DISC
	@		15MG/ML	N71619 001	Feb 28, 1991	Apr	DISC
			RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER				
	@	HOSPIRA	30MG/100ML	N71438 001	Jan 22, 1991	Apr	DISC

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB		HUAHAI US INC	EQ 0.25MG BASE	N78110 001	May 05, 2008	Apr	CAHN
AB			EQ 0.5MG BASE	N78110 002	May 05, 2008	Apr	CAHN
AB			EQ 1MG BASE	N78110 003	May 05, 2008	Apr	CAHN
AB			EQ 2MG BASE	N78110 004	May 05, 2008	Apr	CAHN
AB			EQ 3MG BASE	N78110 005	May 05, 2008	Apr	CAHN
AB			EQ 4MG BASE	N78110 006	May 05, 2008	Apr	CAHN
AB		ZYDUS PHARMS USA INC	EQ 0.25MG BASE	N90411 001	Jun 01, 2009	May	NEWA
AB			EQ 0.5MG BASE	N90411 002	Jun 01, 2009	May	NEWA
AB			EQ 1MG BASE	N90411 003	Jun 01, 2009	May	NEWA
AB			EQ 2MG BASE	N90411 004	Jun 01, 2009	May	NEWA
AB			EQ 3MG BASE	N90411 005	Jun 01, 2009	May	NEWA
AB			EQ 4MG BASE	N90411 006	Jun 01, 2009	May	NEWA
AB			EQ 5MG BASE	N90411 007	Jun 01, 2009	May	NEWA

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

		SMITHKLINE BEECHAM	EQ 6MG BASE	N22008 006	Apr 10, 2009	Apr	NEWA
--	--	--------------------	-------------	------------	--------------	-----	------

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+		EUSA PHARMA USA	50mCi/ML	N20570 001	Mar 28, 1997	May	CAHN
---	--	-----------------	----------	------------	--------------	-----	------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

	@	ENDO PHARMS	5MG	N74565 001	Aug 02, 1996	Apr	DISC
--	---	-------------	-----	------------	--------------	-----	------

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

@ SIEGFRIED

5MG

N74672 001 Apr 01, 1997 Apr DISC

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB AUSTARPHARMA LLC

EQ 25MG BASE

N78677 001 Mar 04, 2009 Feb NEWA

AB

EQ 50MG BASE

N78677 002 Mar 04, 2009 Feb NEWA

AB

EQ 100MG BASE

N78677 003 Mar 04, 2009 Feb NEWA

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB LUPIN

5MG

N78103 005 Apr 14, 2009 Mar NEWA

SODIUM PHOSPHATE, P-32

SOLUTION; INJECTION, ORAL

SODIUM PHOSPHATE P 32

@ MALLINCKRODT

0.67mCi/ML

N11777 001 May DISC

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXATE

AA KVK TECH

454GM/BOT

N40905 001 Mar 30, 2009 Mar NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN NORDIFLEX

NOVO NORDISK INC

30MG/3ML

N21148 007 Mar 10, 2009 Mar NEWA

SORAFENIB TOSYLATE

TABLET; ORAL

NEXAVAR

>A> + BAYER HLTHCARE

EQ 200MG BASE

N21923 001 Dec 20, 2005 Jun CAHN

>D> + BAYER PHARMS

EQ 200MG BASE

N21923 001 Dec 20, 2005 Jun CAHN

STANZOLOL

TABLET; ORAL

WINSTROL

@ LUNDBECK INC

2MG

N12885 001 May 14, 1984 Mar CAHN

STAVUDINE

FOR SOLUTION; ORAL

STAVUDINE

AA CIPLA LTD

1MG/ML

N78030 001 Mar 20, 2009 Mar NEWA

SUCCIMER

CAPSULE; ORAL

CHEMET

+ LUNDBECK INC

100MG

N19998 002 Jan 30, 1991 Mar CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB	PERRIGO CO TENNESSEE	10%	N78649 001	Mar 23, 2009	Mar	NEWA
AB	TARO	10%	N78668 001	May 20, 2009	May	NEWA

SOLUTION/DROPS; OPHTHALMIC

SULF-10

@	NOVARTIS	10%	N80025 001		Apr	DISC
---	----------	-----	------------	--	-----	------

SULFACETAMIDE SODIUM

@	ALCON	30%	N89068 001	May 05, 1987	Apr	DISC
---	-------	-----	------------	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOPRIM

AB	PAR PHARM	400MG;80MG	N70022 001	Feb 15, 1985	Mar	CMFD
----	-----------	------------	------------	--------------	-----	------

SULFAMETHOPRIM-DS

AB	PAR PHARM	800MG;160MG	N70032 001	Feb 15, 1985	Mar	CMFD
----	-----------	-------------	------------	--------------	-----	------

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@	SANDOZ	800MG;160MG	N70890 001	Nov 13, 1986	Mar	DISC
---	--------	-------------	------------	--------------	-----	------

>D> SULFISOXAZOLE ACETYL

>D> SUSPENSION; ORAL

>D> GANTRISIN PEDIATRIC

>D>	+	ROCHE	EQ 500MG BASE/5ML	N09182 004		Jun	DISC
-----	---	-------	-------------------	------------	--	-----	------

>A>	@		EQ 500MG BASE/5ML	N09182 004		Jun	DISC
-----	---	--	-------------------	------------	--	-----	------

SULINDAC

TABLET; ORAL

SULINDAC

@	SANDOZ	150MG	N72712 001	Aug 30, 1991	Mar	DISC
---	--------	-------	------------	--------------	-----	------

@		200MG	N72713 001	Aug 30, 1991	Mar	DISC
---	--	-------	------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX

AP	+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N20080 001	Dec 28, 1992	Jan	CFTG
----	---	-----------------	-------------------------------------	------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

AP	APP PHARMS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N79242 001	Mar 02, 2009	Feb	NEWA
----	------------	-------------------------------------	------------	--------------	-----	------

AP	BEDFORD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N79123 001	Feb 06, 2009	Jan	NEWA
----	---------	-------------------------------------	------------	--------------	-----	------

>A>	AP	JHP PHARMS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N77871 001	Jul 09, 2009	Jun	NEWA
-----	----	------------	-------------------------------------	------------	--------------	-----	------

AP	SANDOZ	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N78067 002	Feb 06, 2009	Jan	NEWA
----	--------	------------------------------------	------------	--------------	-----	------

AP		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78067 001	Feb 06, 2009	Jan	NEWA
----	--	-------------------------------------	------------	--------------	-----	------

AP	TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N78318 001	Feb 06, 2009	Jan	NEWA
----	-----------------	------------------------------------	------------	--------------	-----	------

AP		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78318 002	Feb 06, 2009	Jan	NEWA
----	--	-------------------------------------	------------	--------------	-----	------

AP		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N77907 001	Feb 06, 2009	Jan	NEWA
----	--	-------------------------------------	------------	--------------	-----	------

AP	WOCKHARDT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N78593 001	Feb 06, 2009	Jan	NEWA
----	-----------	-------------------------------------	------------	--------------	-----	------

TABLET; ORAL

IMITREX

AB	GLAXOSMITHKLINE	EQ 25MG BASE	N20132 002	Jun 01, 1995	Jan	CFTG
----	-----------------	--------------	------------	--------------	-----	------

TABLET; ORAL

IMITREX

AB	GLAXOSMITHKLINE	EQ 50MG BASE	N20132 003	Jun 01, 1995	Jan	CFTG
AB	+	EQ 100MG BASE	N20132 001	Jun 01, 1995	Jan	CFTG
SUMATRIPTAN SUCCINATE						
AB	RANBAXY	EQ 100MG BASE	N76572 001	Feb 09, 2009	Jan	NEWA
AB	TEVA	EQ 25MG BASE	N76840 001	Feb 09, 2009	Jan	NEWA
AB		EQ 50MG BASE	N76840 002	Feb 09, 2009	Jan	NEWA
AB		EQ 100MG BASE	N76840 003	Feb 09, 2009	Jan	NEWA

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

CPPI CV

		EQ 37.5MG BASE	N21938 004	Mar 31, 2009	Mar	NEWA
--	--	----------------	------------	--------------	-----	------

TADALAFIL

TABLET; ORAL

ADCIRCA

+	ELI LILLY CO	20MG	N22332 001	May 22, 2009	May	NEWA
---	--------------	------	------------	--------------	-----	------

TAMOXIFEN CITRATE

TABLET; ORAL

TAMOXIFEN CITRATE

@ ROXANE

		EQ 10MG BASE	N76027 001	Feb 20, 2003	Mar	DISC
--	--	--------------	------------	--------------	-----	------

@

		EQ 20MG BASE	N76027 002	Feb 20, 2003	Mar	DISC
--	--	--------------	------------	--------------	-----	------

TAPENTADOL HYDROCHLORIDE

TABLET; ORAL

TAPENTADOL HYDROCHLORIDE

>D>	ORTHO MCNEIL JANSSEN	50MG	N22304 001	Nov 20, 2008	Jun	CPOT
>A>		EQ 50MG BASE	N22304 001	Nov 20, 2008	Jun	CPOT
>D>		75MG	N22304 002	Nov 20, 2008	Jun	CPOT
>A>		EQ 75MG BASE	N22304 002	Nov 20, 2008	Jun	CPOT
>D>	+	100MG	N22304 003	Nov 20, 2008	Jun	CPOT
>A>	+	EQ 100MG BASE	N22304 003	Nov 20, 2008	Jun	CPOT

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION

NEUROLITE

LANTHEUS MEDCL

		N/A	N20256 001	Nov 23, 1994	Apr	CPOT
--	--	-----	------------	--------------	-----	------

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

+	DRAXIMAGE	N/A	N18035 001		Apr	CTEC
---	-----------	-----	------------	--	-----	------

DRAXIMAGE MDP-25

>D>	@ DRAXIMAGE	N/A	N18035 002	Feb 27, 2004	Jun	CMFD
-----	-------------	-----	------------	--------------	-----	------

>A>	+	N/A	N18035 002	Feb 27, 2004	Jun	CMFD
-----	---	-----	------------	--------------	-----	------

@

		N/A	N18035 002	Feb 27, 2004	Apr	DISC
--	--	-----	------------	--------------	-----	------

TECHNETIUM TC 99M MPI MDP

@ GE HEALTHCARE

		N/A	N18141 002	Jun 12, 1989	Apr	DISC
--	--	-----	------------	--------------	-----	------

@

		N/A	N18141 001		Apr	DISC
--	--	-----	------------	--	-----	------

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M SESTAMIBI

AP	CARDINAL HEALTH 414	N/A	N78809	001	Apr 28, 2009	Apr	NEWA
AP	DRAXIMAGE	N/A	N78806	001	Apr 29, 2009	Apr	NEWA
>A>	AP	PHARMALUCENCE	N79157	001	Jul 10, 2009	Jun	NEWA

TELBIVUDINE

SOLUTION; ORAL

TYZEKA

+	NOVARTIS	100MG/5ML	N22154	001	Apr 28, 2009	Apr	NEWA
---	----------	-----------	--------	-----	--------------	-----	------

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

>D>		TYCO HLTHCARE	22.5MG	N18163	004	Nov 02, 2004	Jun	CFTG
>A>	AB		22.5MG	N18163	004	Nov 02, 2004	Jun	CFTG
>A>		TEMAZEPAM						
>A>	AB	MYLAN	22.5MG	N70920	003	Jun 12, 2009	Jun	NEWA
		@ NOVEL LABS INC	30MG	N71457	001	Apr 21, 1987	Mar	CAHN

TEMOZOLOMIDE

POWDER; INTRAVENOUS

TEMODAR

+	SCHERING	100MG/VIAL	N22277	001	Feb 27, 2009	Feb	NEWA
---	----------	------------	--------	-----	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB	IVAX PHARMS	EQ 1MG BASE	N75614	002	Jan 30, 2001	May	CMFD
AB		EQ 2MG BASE	N75614	001	Jan 30, 2001	May	CMFD
AB		EQ 5MG BASE	N75614	003	Jan 30, 2001	May	CMFD
AB		EQ 10MG BASE	N75614	004	Jan 30, 2001	May	CMFD

TABLET; ORAL

HYTRIN

	ABBOTT	EQ 1MG BASE	N19057	001	Aug 07, 1987	Mar	CTEC
+		EQ 2MG BASE	N19057	002	Aug 07, 1987	Mar	CTEC
		EQ 5MG BASE	N19057	003	Aug 07, 1987	Mar	CTEC
		EQ 10MG BASE	N19057	004	Aug 07, 1987	Mar	CTEC

TERAZOSIN HYDROCHLORIDE

@	SANDOZ	EQ 1MG BASE	N74315	001	Dec 31, 1998	Mar	DISC
@		EQ 2MG BASE	N74315	002	Dec 31, 1998	Mar	DISC
@		EQ 5MG BASE	N74315	003	Dec 31, 1998	Mar	DISC
@		EQ 10MG BASE	N74315	004	Dec 31, 1998	Mar	DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

AP	HIKMA FARMACEUTICA	1MG/ML	N78630	001	May 20, 2009	May	NEWA
----	--------------------	--------	--------	-----	--------------	-----	------

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

	LILLY	0.6MG/2.4ML (0.25MG/ML)	N21318	002	Jun 25, 2008	Feb	NEWA
+		0.75MG/3ML (0.25MG/ML)	N21318	001	Nov 26, 2002	Feb	CPOT

TESTOSTERONE

	GEL; TRANSDERMAL						
	ANDROGEL						
		UNIMED PHARMS	1% (2.5GM/PACKET)	N21015	001	Feb 28, 2000	Mar CTEC
BX	+		1% (5GM/PACKET)	N21015	002	Feb 28, 2000	Mar CTEC
	TESTOSTERONE						
		@ WATSON LABS	1% (5GM/PACKET)	N76737	002	Jan 27, 2006	Mar DISC
		@	1% (2.5GM/PACKET)	N76737	001	Jan 27, 2006	Mar DISC

TESTOSTERONE ENANTHATE

	INJECTABLE; INJECTION						
	DELATESTRYL						
		@ ENDO PHARM	200MG/ML	N09165	001		Apr CAHN
AO	+		200MG/ML	N09165	003		Apr CAHN
		@ ENDO PHARMS	200MG/ML	N09165	001		Mar CAHN
AO	+		200MG/ML	N09165	003		Mar CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

	SOLUTION; NASAL						
	TYZINE						
	+	NYCOMED US	0.05%	N86576	002		Apr CAHN
			0.1%	N86576	001		Apr CAHN
	SPRAY; NASAL						
	TYZINE						
	+	NYCOMED US	0.1%	N86576	003		Apr CAHN

THEOPHYLLINE

	ELIXIR; ORAL						
	ELIXOPHYLLIN						
>D>	AA	FOREST LABS	80MG/15ML	N85186	001		Jun CRLD
>A>		+	80MG/15ML	N85186	001		Jun CRLD
>D>	THEOPHYLLINE						
>D>	AA	MORTON GROVE	80MG/15ML	N86748	001		Jun DISC
>A>		@	80MG/15ML	N86748	001		Jun DISC
>D>	AA	PRECISION DOSE	80MG/15ML	N85863	001		Jun DISC
>A>		@	80MG/15ML	N85863	001		Jun DISC
	AA		80MG/15ML	N85863	001		Apr CAHN
>D>	AA	TARO	80MG/15ML	N89626	001	Oct 28, 1988	Jun DISC
>A>		@	80MG/15ML	N89626	001	Oct 28, 1988	Jun DISC
	SOLUTION; ORAL						
	THEOPHYLLINE						
		@ ROXANE	80MG/15ML	N87449	001	Sep 15, 1983	Mar DISC

>D>	<u>THIABENDAZOLE</u>						
>D>	TABLET, CHEWABLE; ORAL						
>D>	MINTEZOL						
>D>	+	MERCK	500MG	N16096	001		Jun DISC
>A>		@	500MG	N16096	001		Jun DISC

THIOTHIXENE

	CAPSULE; ORAL						
	NAVANE						
>D>		PFIZER	20MG	N16584	005		Jun DISC
>A>		@	20MG	N16584	005		Jun DISC

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL							
>D>	TICLID						
>D>	AB + ROCHE PALO	250MG	N19979	002	Oct 31, 1991	Jun	DISC
>A>	@	250MG	N19979	002	Oct 31, 1991	Jun	DISC
TICLOPIDINE HYDROCHLORIDE							
>D>	AB TEVA	250MG	N75149	001	Aug 20, 1999	Jun	CRLD
>A>	AB +	250MG	N75149	001	Aug 20, 1999	Jun	CRLD

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC							
TIMOPTIC							
AT	+ ATON	EQ 0.25% BASE	N18086	001		Feb	CAHN
AT	+	EQ 0.5% BASE	N18086	002		Feb	CAHN
TIMOPTIC IN OCUDOSE							
	+ ATON	EQ 0.25% BASE	N19463	001	Nov 05, 1986	Feb	CAHN
	+	EQ 0.5% BASE	N19463	002	Nov 05, 1986	Feb	CAHN
SOLUTION, GEL FORMING/DROPS; OPHTHALMIC							
TIMOPTIC-XE							
AB	+ ATON	EQ 0.25% BASE	N20330	001	Nov 04, 1993	Feb	CAHN
AB	+	EQ 0.5% BASE	N20330	002	Nov 04, 1993	Feb	CAHN
TABLET; ORAL							
TIMOLOL MALEATE							
	MYLAN	5MG	N72666	001	Jun 08, 1990	Mar	CTEC
		10MG	N72667	001	Jun 08, 1990	Mar	CTEC
	+	20MG	N72668	001	Jun 08, 1990	Mar	CTEC
	@ SANDOZ	5MG	N72550	001	Apr 13, 1989	Mar	DISC
	@	10MG	N72551	001	Apr 13, 1989	Mar	DISC
	@	20MG	N72552	001	Apr 13, 1989	Mar	DISC

TOLAZAMIDE

TABLET; ORAL							
TOLAZAMIDE							
	IVAX PHARMS	100MG	N18894	001	Nov 02, 1984	Mar	CTEC
	@ SANDOZ	100MG	N71633	001	Dec 09, 1987	Mar	DISC
	@	250MG	N70289	001	Mar 13, 1986	Mar	DISC
	@	500MG	N70290	001	Mar 13, 1986	Mar	DISC

TOLBUTAMIDE

TABLET; ORAL							
TOLBUTAMIDE							
	@ SANDOZ	500MG	N86574	001		Mar	DISC

TOLMETIN SODIUM

TABLET; ORAL							
TOLMETIN SODIUM							
	@ SANDOZ	EQ 200MG BASE	N73588	001	Jul 31, 1992	Mar	DISC
	@	EQ 600MG BASE	N74002	001	Sep 27, 1993	Mar	DISC

TOLVAPTAN

TABLET; ORAL							
SAMSCA							
	OTSUKA AMERICA PHARM	15MG	N22275	001	May 19, 2009	May	NEWA
	+	30MG	N22275	002	May 19, 2009	May	NEWA
	@	60MG	N22275	003	May 19, 2009	May	DISC

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX

AB	ORTHO MCNEIL JANSSEN	15MG	N20844 001	Oct 26, 1998	Mar	CFTG
AB	+	25MG	N20844 002	Oct 26, 1998	Mar	CFTG

TOPIRAMATE

AB	BARR	15MG	N76448 001	Apr 15, 2009	Mar	NEWA
AB		25MG	N76448 002	Apr 15, 2009	Mar	NEWA
AB	COBALT LABS INC	15MG	N77868 001	Apr 15, 2009	Mar	NEWA
AB		25MG	N77868 002	Apr 15, 2009	Mar	NEWA
AB	TEVA	15MG	N76575 001	Apr 17, 2009	Mar	NEWA
AB		25MG	N76575 002	Apr 17, 2009	Mar	NEWA

TABLET; ORAL

TOPAMAX

AB	+	ORTHO MCNEIL JANSSEN	25MG	N20505 004	Dec 24, 1996	Mar	CFTG
AB			50MG	N20505 005	Dec 24, 1996	Mar	CFTG
AB			100MG	N20505 001	Dec 24, 1996	Mar	CFTG
AB			200MG	N20505 002	Dec 24, 1996	Mar	CFTG

TOPIRAMATE

AB	APOTEX INC	25MG	N77733 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77733 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77733 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77733 004	Mar 27, 2009	Mar	NEWA
AB	AUROBINDO PHARMA	25MG	N78462 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N78462 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N78462 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N78462 004	Mar 27, 2009	Mar	NEWA
AB	BARR	25MG	N76315 001	Mar 27, 2009	Mar	NEWA
AB		100MG	N76315 002	Mar 27, 2009	Mar	NEWA
AB		200MG	N76315 003	Mar 27, 2009	Mar	NEWA
AB	CIPLA LTD	25MG	N76343 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76343 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76343 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76343 004	Mar 27, 2009	Mar	NEWA
AB	COBALT LABS INC	25MG	N77643 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77643 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77643 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77643 004	Mar 27, 2009	Mar	NEWA
AB	GLENMARK GENERICS	25MG	N77627 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77627 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77627 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77627 004	Mar 27, 2009	Mar	NEWA
AB	INVAGEN PHARMS	25MG	N79162 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N79162 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N79162 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N79162 004	Mar 27, 2009	Mar	NEWA
AB	MYLAN	25MG	N76314 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76314 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76314 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76314 004	Mar 27, 2009	Mar	NEWA
AB	PAR PHARM	25MG	N76311 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76311 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76311 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76311 004	Mar 27, 2009	Mar	NEWA
AB	PLIVA HRVATSKA DOO	25MG	N77905 001	Mar 30, 2009	Mar	NEWA

TABLET; ORAL

TOPIRAMATE

AB	PLIVA HRVATSKA DOO	50MG	N77905 002	Mar 30, 2009	Mar	NEWA
AB		100MG	N77905 003	Mar 30, 2009	Mar	NEWA
AB		200MG	N77905 004	Mar 30, 2009	Mar	NEWA
AB	RANBAXY	25MG	N76327 001	Mar 27, 2009	Mar	NEWA
AB		100MG	N76327 002	Mar 27, 2009	Mar	NEWA
AB		200MG	N76327 003	Mar 27, 2009	Mar	NEWA
AB	ROXANE	25MG	N76306 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76306 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76306 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76306 004	Mar 27, 2009	Mar	NEWA
AB	SUN PHARM INDS LTD	25MG	N90278 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N90278 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N90278 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N90278 004	Mar 27, 2009	Mar	NEWA
AB	TEVA	25MG	N76317 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76317 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76317 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76317 004	Mar 27, 2009	Mar	NEWA
AB	TORRENT PHARMS	25MG	N79153 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N79153 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N79153 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N79153 004	Mar 27, 2009	Mar	NEWA
AB	UNICHEM	25MG	N90162 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N90162 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N90162 003	Mar 27, 2009	Mar	NEWA
AB	ZYDUS PHARMS USA INC	25MG	N78235 001	Mar 27, 2009	Mar	NEWA
AB		50MG	N78235 002	Mar 27, 2009	Mar	NEWA
AB		100MG	N78235 003	Mar 27, 2009	Mar	NEWA
AB		200MG	N78235 004	Mar 27, 2009	Mar	NEWA

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB	HETERO DRUGS	5MG	N79234 001	Jan 27, 2009	Jan	NEWA
AB		10MG	N79234 002	Jan 27, 2009	Jan	NEWA
AB		20MG	N79234 003	Jan 27, 2009	Jan	NEWA
AB		100MG	N79234 004	Jan 27, 2009	Jan	NEWA

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

BC	+ PURDUE PHARMA	100MG	N21745 001	Dec 30, 2008	Mar	CAHN
BC		200MG	N21745 002	Dec 30, 2008	Mar	CAHN
BC		300MG	N21745 003	Dec 30, 2008	Mar	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

TRAMADOL HYDROCHLORIDE

@ ETHYPHARM NORTH

50MG

N21693 001 May 05, 2005 Mar CAHN

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB	ALVOGEN	50MG	N71636 001	Apr 18, 1988	Feb	CAHN
AB		100MG	N71514 001	Apr 18, 1988	Feb	CAHN
AB	APOTEX INC	300MG	N71196 003	Apr 26, 1999	May	CTEC

TABLET; ORALTRAZODONE HYDROCHLORIDE

AB	MATRIX LABS LTD	50MG	N90514 001	Jun 02, 2009	May	NEWA
AB		100MG	N90514 002	Jun 02, 2009	May	NEWA
AB		150MG	N90514 003	Jun 02, 2009	May	NEWA
AB		300MG	N90514 004	Jun 02, 2009	May	NEWA
	@ SANDOZ	50MG	N72484 001	Apr 30, 1990	Mar	DISC
	@	100MG	N72483 001	Apr 30, 1990	Mar	DISC

TRETINOINGEL; TOPICALATRALIN

>D>	+ CORIA	0.05%	N22070 001	Jul 26, 2007	Jun	CAHN
>A>	+ DOW PHARM SCIENCES	0.05%	N22070 001	Jul 26, 2007	Jun	CAHN

TRIAMCINOLONE ACETONIDEINJECTABLE; INJECTIONKENALOG-10

AB	APOTHECON	10MG/ML	N12041 001		May	CFTG
----	-----------	---------	------------	--	-----	------

KENALOG-40

AB	+ APOTHECON	40MG/ML	N14901 001		May	CFTG
----	-------------	---------	------------	--	-----	------

TRIAMCINOLONE ACETONIDE

AB	SANDOZ	10MG/ML	N90166 001	May 27, 2009	May	NEWA
AB		40MG/ML	N90164 001	May 27, 2009	May	NEWA

TROSPIDIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORALSANCTURA XR

	+ ALLERGAN	60MG	N22103 001	Aug 03, 2007	Apr	CAHN
	+ ENDO PHARMS	60MG	N22103 001	Aug 03, 2007	Mar	CAHN

TABLET; ORALSANCTURA

	+ ALLERGAN	20MG	N21595 001	May 28, 2004	Apr	CAHN
	+ ENDO PHARMS	20MG	N21595 001	May 28, 2004	Mar	CAHN

TRYPAN BLUESOLUTION; OPHTHALMICMEMBRANEBLUE

	+ DORC	0.15%	N22278 001	Feb 20, 2009	Feb	NEWA
--	--------	-------	------------	--------------	-----	------

URSODIOLTABLET; ORALURSO 250

AB	AXCAN	250MG	N20675 001	Dec 10, 1997	May	CFTG
----	-------	-------	------------	--------------	-----	------

URSO FORTE

AB	+ AXCAN	500MG	N20675 002	Jul 21, 2004	May	CFTG
----	---------	-------	------------	--------------	-----	------

URSODIOL

AB	TEVA PHARMS	250MG	N79184 001	May 13, 2009	May	NEWA
AB		500MG	N79184 002	May 13, 2009	May	NEWA

VALRUBICINSOLUTION; INTRAVESICALVALSTAR PRESERVATIVE FREE

	+ ENDO PHARM	40MG/ML	N20892 001	Sep 25, 1998	Apr	CAHN
	+ ENDO PHARMS	40MG/ML	N20892 001	Sep 25, 1998	Mar	CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	+	ABRAXIS PHARM	EQ 10GM BASE/VIAL	N62663 004	Nov 28, 1997	Apr	CTEC
AP		HOSPIRA	EQ 750MG BASE/VIAL	N62912 002	Jan 07, 2009	May	CTEC
AP			EQ 750MG BASE/VIAL	N62933 002	May 27, 2009	May	NEWA
AP		HOSPIRA INC	EQ 10GM BASE/VIAL	N65455 001	Apr 29, 2009	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

>A>	AP	SUN PHARMA GLOBAL	10MG/VIAL	N79001 001	Jun 17, 2009	Jun	NEWA
>A>	AP		20MG/VIAL	N79001 002	Jun 17, 2009	Jun	NEWA

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

	@	BEDFORD	2.5MG/ML	N72888 001	Jul 28, 1995	Apr	DISC
--	---	---------	----------	------------	--------------	-----	------

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

	@	SANDOZ	40MG	N73168 001	Jul 31, 1992	Mar	DISC
	@		80MG	N71423 001	May 24, 1988	Mar	DISC
	@		120MG	N71424 001	May 25, 1988	Mar	DISC

ZOLPIDEM TARTRATE

TABLET; SUBLINGUAL

EDLUAR

>D>		OREXO AB	5MG	N21997 001	Mar 13, 2009	Jun	CAHN
>A>			5MG	N21997 001	Mar 13, 2009	Jun	CAHN
			5MG	N21997 001	Mar 13, 2009	Mar	NEWA
>D>	+		10MG	N21997 002	Mar 13, 2009	Jun	CAHN
>A>	+		10MG	N21997 002	Mar 13, 2009	Jun	CAHN
	+		10MG	N21997 002	Mar 13, 2009	Mar	NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

	@	MUTUAL PHARM	25MG	N77635 001	Dec 22, 2005	May	DISC
	@		50MG	N77635 002	Dec 22, 2005	May	DISC
	@		100MG	N77635 003	Dec 22, 2005	May	DISC

OTC DRUG PRODUCT LIST - 29TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

2-1

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

OHM LABS 650MG N76200 001 Mar 19, 2002 Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD 5MG/5ML N90474 002 Mar 30, 2009 Mar NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

DR REDDYS LABS LTD 5MG/5ML N90474 001 Mar 30, 2009 Mar NEWA

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

ORCHID HLTHCARE 5MG N78862 001 Feb 19, 2009 Feb NEWA

10MG N78862 002 Feb 19, 2009 Feb NEWA

>A> UNICHEM 5MG N78680 003 Jun 26, 2009 Jun NEWA

>A> 10MG N78680 004 Jun 26, 2009 Jun NEWA

CETIRIZINE HYDROCHLORIDE HIVES

ORCHID HLTHCARE 5MG N78862 003 Feb 19, 2009 Feb NEWA

10MG N78862 004 Feb 19, 2009 Feb NEWA

>A> UNICHEM 5MG N78680 001 Jun 26, 2009 Jun NEWA

>A> 10MG N78680 002 Jun 26, 2009 Jun NEWA

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

AVANTHI INC 12MG N40829 001 May 13, 2009 Apr NEWA

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

+ RECKITT BENCKISER EQ 30MG HBR/5ML N18658 001 Oct 08, 1982 Feb CAHN

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET; ORAL

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

>A> DR REDDYS LABS LTD 38MG;200MG N90619 001 Jul 08, 2009 Jun NEWA

EPINEPHRINE

AEROSOL, METERED; INHALATION

>D> PRIMATENE MIST

>D> + WYETH CONS 0.2MG/INH N16126 001 Jun DISC

>A> @ 0.2MG/INH N16126 001 Jun DISC

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

>D> BRONITIN MIST

>D> WYETH CONS 0.3MG/INH N16126 002 Jun DISC

>A> @ 0.3MG/INH N16126 002 Jun DISC

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

	BANNER PHARMACAPS	EQ 200MG FREE ACID AND POTASSIUM SALT	N78682 001	Mar 24, 2009	Mar	NEWA
>A>	DR REDDYS LABS LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	N77338 001	Jul 10, 2009	Jun	NEWA
>A>	MARKSANS PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	N79205 001	Jun 26, 2009	Jun	NEWA

MIDOL LIQUID GELS

	+ BANNER PHARMACAPS	200MG	N21472 001	Oct 18, 2002	Feb	CTNA
--	---------------------	-------	------------	--------------	-----	------

TABLET; ORAL

IBUPROFEN

	@ SANDOZ	200MG	N70733 001	Sep 19, 1986	Mar	DISC
--	----------	-------	------------	--------------	-----	------

MEDIPREN

	@ MCNEIL	200MG	N70475 001	Feb 06, 1986	Apr	DISC
--	----------	-------	------------	--------------	-----	------

	@	200MG	N71215 001	Jun 26, 1986	Apr	DISC
--	---	-------	------------	--------------	-----	------

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

	@ LILLY	50 UNITS/ML;50 UNITS/ML	N20100 001	Apr 29, 1992	Jan	DISC
--	---------	-------------------------	------------	--------------	-----	------

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PREVACID 24 HR

	+ NOVARTIS	15MG	N22327 001	May 18, 2009	May	NEWA
--	------------	------	------------	--------------	-----	------

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

PROSTEP

>D>						
>D>	+ AVEVA	11MG/24HR	N19983 003	Dec 23, 1998	Jun	DISC
>A>	@	11MG/24HR	N19983 003	Dec 23, 1998	Jun	DISC
>D>	+	22MG/24HR	N19983 004	Dec 23, 1998	Jun	DISC
>A>	@	22MG/24HR	N19983 004	Dec 23, 1998	Jun	DISC

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

	IVAX PHARMS	EQ 2MG BASE	N76880 001	Feb 18, 2009	Feb	NEWA
		EQ 4MG BASE	N77850 001	Feb 18, 2009	Feb	NEWA
>A>	WATSON LABS	EQ 2MG BASE	N79044 001	Jul 08, 2009	Jun	NEWA
>A>		EQ 2MG BASE	N79216 001	Jul 08, 2009	Jun	NEWA
>A>		EQ 4MG BASE	N79038 001	Jul 08, 2009	Jun	NEWA
>A>		EQ 4MG BASE	N79219 001	Jul 08, 2009	Jun	NEWA

TROCHE/LOZENGE; ORAL

NICORETTE

	GLAXOSMITHKLINE CONS	EQ 2MG BASE	N22360 001	May 18, 2009	May	NEWA
	+	EQ 4MG BASE	N22360 002	May 18, 2009	May	NEWA
	NICOTINE POLACRILEX					
>A>	PERRIGO R AND D	EQ 2MG BASE	N90711 001	Jul 10, 2009	Jun	NEWA
>A>		EQ 2MG BASE	N90821 001	Jul 10, 2009	Jun	NEWA
>A>		EQ 4MG BASE	N90711 002	Jul 10, 2009	Jun	NEWA
>A>		EQ 4MG BASE	N90821 002	Jul 10, 2009	Jun	NEWA

POTASSIUM IODIDE

SOLUTION; ORAL

THYROSHIELD

+ FLEMING

65MG/ML

N77218 001 Jan 12, 2005 Apr CRLD

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE

@ SANDOZ

EQ 75MG BASE

N75519 001 Sep 26, 2002 Mar DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 06 JUNE 2009

NO JUNE 2009 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2009 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
022320 001	4717720	May 31, 2010	DS DP			
	RE34440	May 31, 2010			U-818	
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
020983 001	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 06, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
<u>ALMOTRIPTAN MALATE - AXERT</u>						
021001 001	5565447	May 07, 2015	DS DP		U-969	
	5565447*PED	Nov 07, 2015				
<u>ALMOTRIPTAN MALATE - AXERT</u>						
021001 002	5565447	May 07, 2015	DS DP		U-969	
	5565447*PED	Nov 07, 2015				
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 001					PC	Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 002					PC	Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 003					PC	Jul 13, 2009
<u>ALPRAZOLAM - ALPRAZOLAM</u>						
078088 004					PC	Jul 13, 2009
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
022325 001	5134127	Jan 23, 2010	DP			
	5376645	Jan 23, 2010	DP			
	6869939	May 04, 2022	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 001	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 002	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 003	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 004	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 005	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 006	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 007	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 008	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 009	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 010	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
021540 011	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 001	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 002	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 003	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 004	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
022314 005	5399578	Mar 21, 2012	DS DP U-3		NC	Apr 30, 2012
	5399578*PED	Sep 21, 2012				
	6294197	Jun 18, 2017	DP U-3			
	6294197*PED	Dec 18, 2017				
<u>AMMONIA, N-13 - AMMONIA N 13</u>						
022119 001					NCE W	Aug 23, 2012 Aug 23, 2012
<u>AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE - PREVPAC</u>						
050757 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5013743	Feb 12, 2010		U-452		
	5013743*PED	Aug 12, 2010				
	5045321	Sep 03, 2008	DP			
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008	DP			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP			
	5433959*PED	Mar 03, 2009				
<u>ANASTROZOLE - ARIMIDEX</u>						
020541 001	RE36617	Dec 27, 2009	DS DP U-946			
<u>ANIDULAFUNGIN - ERAXIS</u>						
021632 001	5965525	Feb 17, 2020	DS DP U-540			
<u>ANIDULAFUNGIN - ERAXIS</u>						
021632 002	5965525	Feb 17, 2020	DS DP U-540			
<u>ARMODAFINIL - NUVIGIL</u>						
021875 001	>A> 4927855	Apr 22, 2010	DS DP U-820			
	>A> 4927855*PED	Oct 22, 2010				
<u>ARMODAFINIL - NUVIGIL</u>						
021875 002	>A> 4927855	Apr 22, 2010	DS DP U-820		NP	Jun 15, 2010
	>A> 4927855*PED	Oct 22, 2010				
	>A> 7297346	Nov 29, 2023	DP			
	>A> 7297346*PED	May 29, 2024				
<u>ARMODAFINIL - NUVIGIL</u>						
021875 003	>A> 4927855	Apr 22, 2010	DS DP U-820			
	>A> 4927855*PED	Oct 22, 2010				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARMODAFINIL - NUVIGIL</u>						
021875 004	>A> 4927855	Apr 22, 2010	DS DP U-820			
	>A> 4927855*PED	Oct 22, 2010				
<u>ARMODAFINIL - NUVIGIL</u>						
021875 005	>A> 4927855	Apr 22, 2010	DS DP U-820		NP	Jun 15, 2010
	>A> 4927855*PED	Oct 22, 2010				
	>A> 7132570	Dec 18, 2023	DS DP			
	>A> 7132570*PED	Jun 18, 2024				
	>A> 7297346	Nov 29, 2023	DP			
	>A> 7297346*PED	May 29, 2024				
	>A> RE37516	Oct 06, 2014	DP U-820			
	>A> RE37516*PED	Apr 06, 2015				
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
021248 001	6982096	Nov 10, 2018	U-651			
<u>ARTEMETHER; LUMEFANTRINE - COARTEM</u>						
022268 001	>A> 5677331	Oct 14, 2014	DP U-977		NCE	Apr 07, 2014
					>A> ODE	Apr 07, 2016
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 001	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 002	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 003	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
020702 004	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
<u>AZITHROMYCIN - AZASITE</u>						
050810 001	5192535	Mar 09, 2010	DP U-709			
	6239113	Mar 31, 2019	U-709			
	6569443	Mar 31, 2019	DP U-709			
	6861411	Nov 25, 2018	U-709			
	7056893	Mar 31, 2019	DP U-709			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
022249 002					I-580	Oct 31, 2011
					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
050819 001	5733886	Mar 31, 2015	DP U-124			
	6117843	Feb 18, 2012	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - DUAC</u>						
050741 001	5466446	Feb 16, 2014	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZYL ALCOHOL - ULESFIA</u>						
022129 001	5858383	Aug 11, 2017	U-970		NCE	Apr 09, 2014
	6139859	Aug 11, 2017	U-970			
	6793931	Jul 11, 2022	DP U-970			
	>A> 7294342	May 19, 2024	U-970			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
022308 001	>A> 5447926	Sep 05, 2012	DS DP U-80		NCE	May 28, 2014
	>A> 6685958	Jun 29, 2021	DP U-80			
	>A> 6699492	Mar 31, 2019	DP U-80			
<u>BETAMETHASONE VALERATE - LUXIQ</u>						
020934 001	7078058	May 24, 2017	DP			
<u>BIMATOPROST - LATISSE</u>						
022369 001					NP	Dec 24, 2011
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA</u>						
050786 001	5196205	Mar 23, 2010	U-933			
	5476669	Mar 23, 2010	U-933			
	6350468	Dec 14, 2018	U-956			
	6350468	Dec 14, 2018	U-932			
<u>BIVALIRUDIN - ANGIOMAX</u>						
020873 001	>A> 5196404	Mar 23, 2010				
	>A> 5196404*PED	Sep 23, 2010				
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
020866 001	>A> 5468755	Nov 21, 2012	U-976		NP	May 05, 2012
	>A> 5679685	Oct 21, 2014	DP			
	>A> 5716957	Feb 10, 2015	U-976			
	>A> 5756513	Nov 21, 2012	U-976			
	>A> 5866584	Nov 21, 2012	U-976			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
020929 001	7524834	Nov 11, 2018	DP U-966			
	7524834*PED	May 11, 2019				
<u>BUDESONIDE - PULMICORT RESPULES</u>						
020929 002	7524834	Nov 11, 2018	DP U-966			
	7524834*PED	May 11, 2019				
<u>BUDESONIDE - PULMICORT RESPULES</u>						
020929 003	7524834	Nov 11, 2018	DP U-966			
	7524834*PED	May 11, 2019				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
021929 001					I-582	Feb 27, 2012
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
021929 002					I-582	Feb 27, 2012
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
021406 001	>A> RE40812	Feb 02, 2021	DP			
<u>CALCITRIOL - VECTICAL</u>						
022087 001					NDF	Jan 23, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE</u>						
020958 001	5075114	May 23, 2010	DP			
	5075114*PED	Nov 23, 2010				
	6814978	Aug 26, 2021	DP			
	6814978*PED	Feb 26, 2022				
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>						
021823 001	5583122	Dec 10, 2013	DS DP U-353			
	5583122*PED	Jun 10, 2014				
	5994329	Jul 17, 2018			U-353	
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018			U-353	
	6015801*PED	Jan 17, 2019				
	6096342	Nov 21, 2011	DP			
	6096342*PED	May 21, 2012				
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
	6432932	Jul 17, 2018			U-595	
	6432932*PED	Jan 17, 2019				
	6465443	Aug 14, 2018	DP			
	6465443*PED	Feb 14, 2019				
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
020838 001	>A> 7538133	Apr 18, 2011	DS			
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
020838 002	>A> 7538133	Apr 18, 2011	DS			
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
020838 003	>A> 7538133	Apr 18, 2011	DS			
<u>CANDESARTAN CILEXETIL - ATACAND</u>						
020838 004	>A> 7538133	Apr 18, 2011	DS			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
021093 001	>A> 7538133	Apr 18, 2011	DS			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
021093 002	>A> 7538133	Apr 18, 2011	DS			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
021093 003	>A> 7538133	Apr 18, 2011	DS			
<u>CICLESONIDE - ALVESCO</u>						
021658 002					NDF NCE	Jan 10, 2011 Oct 20, 2011
<u>CICLESONIDE - ALVESCO</u>						
021658 003					NDF NCE	Jan 10, 2011 Oct 20, 2011
<u>CIPROFLOXACIN HYDROCHLORIDE - CETRAXAL</u>						
021918 001					NDF	May 01, 2012
<u>CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPRO HC</u>						
020805 001	5843930	Jun 06, 2015	U-646			
<u>CLARITHROMYCIN - BIAXIN XL</u>						
050775 001	6551616	Jul 15, 2017	U-924			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBETASOL PROPIONATE - OLUX</u>						
021142 001	6126920	Mar 01, 2016	U-484			
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
020839 002	4847265	Nov 17, 2011	DS DP			
	6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
021141 001	5607669	Jun 10, 2014	U-323			
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014	U-323			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014				
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	U-323			
	5917007*PED	Oct 29, 2014				
	5919832	Jun 10, 2014				
	5919832*PED	Dec 10, 2014				
	6066678	Jun 10, 2014	U-323			
	6066678*PED	Dec 10, 2014				
	6433026	Jun 10, 2014				
	6433026*PED	Dec 10, 2014				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
021176 001	5607669	Jun 10, 2014	U-323		I-553	Jan 18, 2011
	5607669*PED	Dec 10, 2014			PED	Jul 18, 2011
	5679717	Apr 29, 2014	U-323			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014	DS			
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	DS U-323			
	5917007*PED	Oct 29, 2014				
	5919832	Apr 29, 2014	DS			
	5919832*PED	Oct 29, 2014				
	6066678	Apr 29, 2014	DS U-323			
	6066678*PED	Oct 29, 2014				
	6433026	Apr 29, 2014	DS			
	6433026*PED	Oct 29, 2014				
	6784254	Apr 29, 2014	DS DP			
	6784254*PED	Oct 29, 2014				
	7101960	Apr 29, 2014	DS DP U-757			
	7101960*PED	Oct 29, 2014				
	7229613	Apr 17, 2022	U-851			
	7229613*PED	Oct 17, 2022				
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
021777 001	>A> 7544372	Nov 14, 2023	U-979			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
021777 002	>A> 7544372	Nov 14, 2023	U-979			
<u>CYCLOSPORINE - SANDIMMUNE</u>						
050625 001	7511014	Feb 16, 2010	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - SANDIMMUNE</u>						
050625 002	7511014	Feb 16, 2010	DP			
<u>CYCLOSPORINE - SANDIMMUNE</u>						
050625 003	7511014	Feb 16, 2010	DP			
<u>DASATINIB - SPRYCEL</u>						
021986 001	7491725	Oct 13, 2025	DS DP		D-120	May 21, 2012
<u>DASATINIB - SPRYCEL</u>						
021986 002	7491725	Oct 13, 2025	DS DP		D-120	May 21, 2012
<u>DASATINIB - SPRYCEL</u>						
021986 003	7491725	Oct 13, 2025	DS DP		D-120	May 21, 2012
<u>DASATINIB - SPRYCEL</u>						
021986 004	>A> 6596746	Jun 28, 2020	DS DP U-780		D-120	May 21, 2012
	>A> 6596746	Jun 28, 2020	DS DP U-748			
	>A> 7125875	Apr 13, 2020	U-780			
	>A> 7125875	Apr 13, 2020	U-779			
	>A> 7153856	Apr 28, 2020	U-780			
	7491725	Oct 13, 2025	DS DP			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
022201 001	5925730	Apr 11, 2017	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
022201 002	5925730	Apr 11, 2017	DS DP U-943			
<u>DESONIDE - DESONATE</u>						
021844 001					>A> NDF	Oct 20, 2009
<u>DEXAMETHASONE - OZURDEX</u>						
022315 001	>A> 6726918	Oct 20, 2020	DP U-985		>A> NDF	Jun 17, 2012
	>A> 7033605	Oct 20, 2020	DP			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
050818 001	5149694	Sep 22, 2009	U-953			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - KAPIDEX</u>						
022287 001	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
<u>DEXLANSOPRAZOLE - KAPIDEX</u>						
022287 002	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
022202 001	>A> 6365180	Jul 16, 2019	DP U-980		>A> NDF	Jun 16, 2012
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM CD</u>						
020062 005	5286497	May 20, 2011	DP			
	5439689	Aug 08, 2012	DP U-107			
	5470584	May 20, 2011	DP			
<u>DINOPROSTONE - CERVIDIL</u>						
020411 001	5269321	Jul 14, 2012	DP U-110			
<u>DIVALPROEX SODIUM - DIVALPROEX SODIUM</u>						
077567 002					PC	Aug 01, 2009
<u>DOXERCALCIFEROL - HECTOROL</u>						
021027 001	5707980	Aug 17, 2010	U-321	Y		
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
022291 001	7473686	Jul 24, 2021	DS DP U-930			
	>A> 7547719	Mar 04, 2024	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
022291 002	7473686	Jul 24, 2021	DS DP U-930			
	>A> 7547719	Mar 04, 2024	DS DP U-930			
<u>EPINEPHRINE - EPIPEN</u>						
019430 001	>A> 7449012	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
019430 002	>A> 7449012	Sep 11, 2025	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 001					NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 002					NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021323 003					NPP	Mar 19, 2012
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
021365 001					NPP	Mar 19, 2012
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021153 001					NPP PED	Apr 28, 2009 Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021153 002					NPP PED	Apr 28, 2009 Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021957 001					>A> M-86 NPP >A> PED PED	Jun 18, 2012 Apr 28, 2009 Dec 18, 2012 Oct 28, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
021957 002					>A> M-86 NPP >A> PED PED	Jun 18, 2012 Apr 28, 2009 Dec 18, 2012 Oct 28, 2009

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
022101 001					NPP PED	Feb 27, 2011 Aug 27, 2011
<u>ESTRADIOL - ELESTRIN</u>						
021813 001	7470433	Aug 03, 2021	DP			
<u>ESTRADIOL - EVAMIST</u>						
022014 001	>A> 6818226	Feb 19, 2017	DP U-889			
	>A> 6818226	Feb 19, 2017	DP U-888			
	>A> 6923983	Feb 19, 2017	DP U-889			
	>A> 6923983	Feb 19, 2017	DP U-888			
	>A> 6978945	Nov 30, 2021	DP			
<u>EVEROLIMUS - AFINITOR</u>						
022334 001	5665772	Sep 09, 2014	DS DP		NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP			
	7297703	Dec 06, 2019	DP			
<u>EVEROLIMUS - AFINITOR</u>						
022334 002	5665772	Sep 09, 2014	DS DP		NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP			
	7297703	Dec 06, 2019	DP			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
021773 001	7521423	Oct 15, 2017	DP			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
021773 002	7521423	Oct 15, 2017	DP			
<u>FEBUXOSTAT - ULORIC</u>						
021856 001	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
<u>FEBUXOSTAT - ULORIC</u>						
021856 002	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
<u>FERUMOXYTOL - FERAHEME</u>						
022180 001					>A> NP	Jun 30, 2012
<u>FLUDARABINE PHOSPHATE - FLUDARABINE PHOSPHATE</u>						
022273 001	7148207	Dec 20, 2022	DP U-944		NDF	Dec 18, 2011
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 001	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 003	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
018936 006	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 001	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 002	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 003	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 004	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
021520 005	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 100</u>						
020833 002	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 250</u>						
020833 003	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 50</u>						
020833 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 001	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Jun 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 002	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
021433 003	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015	U-710			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015	U-582			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015	U-583			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
021077 001	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
021077 002	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
021077 003	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
021254 001	5658549	Aug 19, 2014	DP			U-738
	5658549*PED	Feb 19, 2015				U-738
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP			U-738
	6253762*PED	Oct 14, 2015				U-738
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6341168	Jun 08, 2018	DP			
	6341168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017				
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021				U-841
	6743413*PED	Dec 01, 2021				U-841
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
021254 002	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6341168	Jun 08, 2018	DP			
	6341168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-841		
	6743413*PED	Dec 01, 2021		U-841		
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
021254 003	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6341168	Jun 08, 2018	DP			
	6341168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021		U-841		
	6743413*PED	Dec 01, 2021		U-841		
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 001					M-83	Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 002					M-83	Apr 14, 2011
<u>FLUVOXAMINE MALEATE - LUVOX</u>						
021519 003					M-83	Apr 14, 2011
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
022244 001	6204257	Jun 07, 2018	DS DP U-945		NCE	Dec 12, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADODIAMIDE - OMNISCAN</u>						
022066 002	5362475	Nov 08, 2011	DS			
<u>GATIFLOXACIN - ZYMAR</u>						
021493 001	4980470	Dec 15, 2009	DS DP			
	4980470*PED	Jun 15, 2010				
	5880283	Dec 05, 2015				
	5880283*PED	Jun 05, 2016				
	6333045	Aug 20, 2019	DP			
	6333045*PED	Feb 20, 2020				
<u>GLATIRAMER ACETATE - COPAXONE</u>						
020622 001					I-594	Feb 27, 2012
<u>GLATIRAMER ACETATE - COPAXONE</u>						
020622 002					I-594	Feb 27, 2012
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
021925 001	>A> 7538125	Jun 19, 2016	DP			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
021925 002	>A> 7538125	Jun 19, 2016	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
019726 001	7500964	Feb 26, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
020578 001	7500964	Feb 26, 2021	DP			
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
021162 003	5591762	Jan 07, 2014	DS DP U-3			
<u>IBUPROFEN - CALDOLOR</u>						
022348 001	>A> 6727286	Nov 27, 2021	DP U-981		>A> NP	Jun 11, 2012
<u>IBUPROFEN - CALDOLOR</u>						
022348 002	>A> 6727286	Nov 27, 2021	DP U-981		>A> NP	Jun 11, 2012
<u>ILOPERIDONE - FANAPT</u>						
022192 001	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 002	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 003	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 004	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 005	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 006	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>ILOPERIDONE - FANAPT</u>						
022192 007	RE39198	Nov 15, 2011	DS DP U-971		NCE	May 06, 2014
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021588 001					I-583	Dec 19, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
021588 002					I-583	Dec 19, 2011
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
021536 001	5750497	May 16, 2019	DS DP U-668			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
021081 001	5656722	Aug 12, 2014	DS DP U-948			
	5656722*PED	Feb 12, 2015				
	7476652	Jul 23, 2023	DP			
	7476652*PED	Jan 23, 2024				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
021629 002					NCE	Apr 16, 2009
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
021629 003					NPP NCE	Oct 24, 2011 Apr 16, 2009
<u>IODIXANOL - VISIPAQUE 270</u>						
020351 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 270</u>						
020808 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
020351 002	RE36418	Jul 12, 2011	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
020808 002	RE36418	Jul 12, 2011	DP			
<u>IXABEPILONE - IXEMPRA KIT</u>						
022065 001	6605599	May 26, 2018	DS DP U-961			
	6670384	Jan 23, 2022	DP U-960			
	6670384	Jan 23, 2022	DP U-959			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
<u>IXABEPILONE - IXEMPRA KIT</u>						
022065 002	6605599	May 26, 2018	DS DP U-961			
	6670384	Jan 23, 2022	DP U-960			
	6670384	Jan 23, 2022	DP U-959			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
<u>LANSOPRAZOLE - PREVACID</u>						
020406 001					M-85 PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
020406 002					M-85 PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
021281 001					M-85 PED	Oct 28, 2011 Apr 28, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LANSOPRAZOLE - PREVACID</u>						
021281 002					M-85 PED	Oct 28, 2011 Apr 28, 2012
<u>LANSOPRAZOLE - PREVACID</u>						
021428 001	7431942	May 17, 2019	DP		M-85 PED	Oct 28, 2011 Apr 28, 2012
	7431942*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID</u>						
021428 002	7431942	May 17, 2019	DP		M-85 PED	Oct 28, 2011 Apr 28, 2012
	7431942*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID 24 HR</u>						
022327 001					NP	May 18, 2012
<u>LANSOPRAZOLE - PREVACID IV</u>						
021566 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	7396841	Aug 17, 2021	DP U-947			
	7396841*PED	Feb 17, 2022				
<u>LANSOPRAZOLE; NAPROXEN - PREVACID NAPRAPAC 500 (COPACKAGED)</u>						
021507 004	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5045321	Sep 03, 2008	DP			
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008	DP			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP			
	5433959*PED	Mar 03, 2009				
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 001	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 002	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 003	5968976	Oct 26, 2018	DP U-613			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 004	5968976	Oct 26, 2018	DP U-613			
<u>LEVETIRACETAM - KEPBRA XR</u>						
022285 002					NDF	Sep 12, 2011
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
022114 001					NPP	Jan 08, 2012
<u>MALATHION - OVIDE</u>						
018613 001	>A> 7560445	Feb 01, 2027	DS DP U-986			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021487 001	5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021487 002	5061703	Apr 11, 2015	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
021627 001	5061703	Apr 11, 2015	U-539			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
022024 001	>A> 4687777	Jan 17, 2011	DS			
	>A> 5965584	Jun 19, 2016	DP U-973			
	>A> 6099859	Mar 20, 2018	DP			
	>A> 6166042	Jun 19, 2016	U-973			
	>A> 6166043	Jun 19, 2016	U-973			
	>A> 6172090	Jun 19, 2016	U-973			
	>A> 6495162	Mar 20, 2018	DP			
	>A> 6790459	Mar 17, 2021	U-974			
	>A> 6866866	Mar 17, 2021	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
022024 002	>A> 4687777	Jan 17, 2011	DS			
	>A> 5965584	Jun 19, 2016	DP U-973			
	>A> 6099859	Mar 20, 2018	DP			
	>A> 6166042	Jun 19, 2016	U-973			
	>A> 6166043	Jun 19, 2016	U-973			
	>A> 6172090	Jun 19, 2016	U-973			
	>A> 6495162	Mar 20, 2018	DP			
	>A> 6790459	Mar 17, 2021	U-974			
	>A> 6866866	Mar 17, 2021	DP			
<u>MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
021308 001	5514698	Mar 21, 2014		Y		
	6153635	Nov 28, 2020		Y		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 001	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 002	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 003	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
022256 004	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	6992110	Nov 05, 2021	U-882			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
050808 002	>A> 7541347	Apr 02, 2027	U-917			
	>A> 7544373	Apr 02, 2027	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
021067 002	5394868	Jun 25, 2012	DP		NPP	Feb 01, 2011
	5394868*PED	Dec 25, 2012				
	5687710	Nov 18, 2014	DP			
	5687710*PED	May 18, 2015				
	5829434	Nov 03, 2015	DP			
	5829434*PED	May 03, 2016				
	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6240918	Feb 20, 2017	DP			
	6240918*PED	Aug 20, 2017				
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
	6503537	Mar 17, 2018	DP			
	6503537*PED	Sep 17, 2018				
	6677322	Jan 27, 2014	U-645			
	6677322*PED	Jul 27, 2014				
	6949532	Jan 27, 2014	U-645			
	6949532*PED	Jul 27, 2014				
<u>MORPHINE SULFATE - AVINZA</u>						
021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
021260 006	6066339	Nov 25, 2017	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
022360 001	>A> 5110605	Aug 21, 2010	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
022360 002	>A> 5110605	Aug 21, 2010	DP			
<u>NITROGLYCERIN - NITROMIST</u>						
021780 001	5869082	Apr 16, 2016	DP			
<u>OLANZAPINE - ZYPREXA</u>						
020592 001	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 002	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 003	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 004	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 005	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA</u>						
020592 006	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 001	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 002	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 003	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
021086 004	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
<u>OMEGA-3-ACID ETHYL ESTERS - LOVAZA</u>						
021654 001	5656667	Apr 10, 2017	DS DP U-822			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
022204 001	7029694	Apr 26, 2020	DP U-318		NDF	Jan 27, 2012
	7179483	Apr 26, 2020	U-318			
<u>PALIPERIDONE - INVEGA</u>						
021999 006	5158952	Oct 27, 2009	DP U-90			
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
020987 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	5997903	Dec 07, 2016				
	5997903*PED	Jun 07, 2017				
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
020987 002	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	5997903	Dec 07, 2016				
	5997903*PED	Jun 07, 2017				
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
022020 001	4758579	Jul 19, 2010	DS DP U-859			
	4758579*PED	Jan 19, 2011				
	>A> 7544370	Feb 07, 2026	DP			
	>A> 7544370*PED	Aug 07, 2026				
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
020988 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	6780881	Nov 17, 2021	DP			
	6780881*PED	May 17, 2022				
	7351723	Nov 17, 2021	DP			
	7351723*PED	May 17, 2022				
<u>PARICALCITOL - ZEMPLAR</u>						
021606 001					>A> I-599	Jun 29, 2012
<u>PARICALCITOL - ZEMPLAR</u>						
021606 002					>A> I-599	Jun 29, 2012
<u>PARICALCITOL - ZEMPLAR</u>						
021606 003					>A> I-599	Jun 29, 2012
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
022159 001	6764678	May 11, 2021	U-967			
	6872390	May 11, 2021	DP			
	7229630	Jun 20, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
021332 002	5814600	Sep 29, 2015	U-639			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-637			
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017	U-640			
	6114304	Sep 05, 2017	U-637			
	6608029	Sep 07, 2013	U-641			
	6608029	Sep 07, 2013	U-640			
	6608029	Sep 07, 2013	U-637			
	6610824	Mar 03, 2011	DS			
	7407934	Mar 08, 2011	U-640			
	7407934	Mar 08, 2011	U-637			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
021332 003	5814600	Sep 29, 2015	U-639			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-637			
	5998367	Mar 08, 2011	DS DP			
	6114304	Sep 05, 2017	U-640			
	6114304	Sep 05, 2017	U-637			
	6608029	Sep 07, 2013	U-641			
	6608029	Sep 07, 2013	U-640			
	6608029	Sep 07, 2013	U-637			
	6610824	Mar 03, 2011	DS			
	7407934	Mar 08, 2011	U-640			
	7407934	Mar 08, 2011	U-637			
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 001	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 002	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 003	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 004	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 005	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 006	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503 PED PED	Oct 20, 2009 Nov 13, 2011 Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 007	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503 PED PED	Oct 20, 2009 Nov 13, 2011 Apr 20, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 001	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575 I-574	Oct 08, 2011 Oct 08, 2011
	5948437	May 28, 2017	DP U-814		NDF	May 17, 2010
	5948437	May 28, 2017	DP U-601		PED	Apr 08, 2012
	5948437*PED	Nov 28, 2017			PED	Nov 17, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 002	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575 I-574	Oct 08, 2011 Oct 08, 2011
	5948437	May 28, 2017	DP U-814		NDF	May 17, 2010
	5948437	May 28, 2017	DP U-601		PED	Apr 08, 2012
	5948437*PED	Nov 28, 2017			PED	Nov 17, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 003	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575 I-574	Oct 08, 2011 Oct 08, 2011
	5948437	May 28, 2017	DP U-814		NDF	May 17, 2010
	5948437	May 28, 2017	DP U-601		PED	Apr 08, 2012
	5948437*PED	Nov 28, 2017			PED	Nov 17, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 004	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575 I-574	Oct 08, 2011 Oct 08, 2011
	5948437	May 28, 2017	DP U-814		NDF	May 17, 2010
	5948437	May 28, 2017	DP U-601		PED	Apr 08, 2012
	5948437*PED	Nov 28, 2017			PED	Nov 17, 2010
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
022047 005	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575 I-574	Oct 08, 2011 Oct 08, 2011
	5948437	May 28, 2017	DP U-814		NDF	May 17, 2010
	5948437	May 28, 2017	DP U-601		PED	Apr 08, 2012
	5948437*PED	Nov 28, 2017			PED	Nov 17, 2010
<u>RASAGILINE MESYLATE - AZILECT</u>						
021641 001	5453446	Feb 07, 2017	U-219			
<u>RASAGILINE MESYLATE - AZILECT</u>						
021641 002	5453446	Feb 07, 2017	U-219			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 001	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 002	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
020630 003	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
<u>REPAGLINIDE - PRANDIN</u>						
020741 001	6677358	Jun 12, 2018	DS DP U-968			
<u>REPAGLINIDE - PRANDIN</u>						
020741 002	6677358	Jun 12, 2018	DS DP U-968			
<u>REPAGLINIDE - PRANDIN</u>						
020741 003	6677358	Jun 12, 2018	DS DP U-968			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 001	5583122	Dec 10, 2013			U-222	
	5583122*PED	Jun 10, 2014				
	6096342	Nov 22, 2011				
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018				
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 002	5583122	Dec 10, 2013			U-222	
	5583122*PED	Jun 10, 2014				
	6096342	Nov 22, 2011				
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018				
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 003	5583122	Dec 10, 2013	DS DP U-756		I-309	Aug 11, 2009
	5583122	Dec 10, 2013	DS DP U-222		PED	Feb 11, 2010
	5583122*PED	Jun 10, 2014				
	5994329	Jul 17, 2018			U-353	
	5994329*PED	Jan 17, 2019				
	6015801	Jul 17, 2018			U-353	
	6015801*PED	Jan 17, 2019				
	6096342	Nov 22, 2011		DP		
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018		DP		
	6165513*PED	Dec 10, 2018				
	6432932	Jul 17, 2018			U-595	
	6432932*PED	Jan 17, 2019				
	6465443	Aug 14, 2018		DP		
	6465443*PED	Feb 14, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 004	5583122	Dec 10, 2013	DS DP U-353		D-105	Apr 16, 2010
	5583122*PED	Jun 10, 2014			PED	Oct 16, 2010
	6096342	Nov 22, 2011	DP U-353			
	6096342*PED	May 22, 2012				
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 005	5583122	Dec 10, 2013	DS DP U-353		NS	Apr 22, 2011
	5583122*PED	Jun 10, 2014			PED	Oct 22, 2011
	6165513	Jun 10, 2018	DP			
	6165513*PED	Dec 10, 2018				
	7192938	May 06, 2023	U-353			
	7192938*PED	Nov 06, 2023				
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
021346 001	>A> 5688801	Nov 18, 2014	U-972		I-597	May 15, 2012
	>A> 5688801	Nov 18, 2014	U-543		I-596	May 15, 2012
	>A> 7547452	Nov 19, 2013	DP			
	>A> 7547452*PED	May 19, 2014				
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
021346 002	>A> 5688801	Nov 18, 2014	U-972		I-597	May 15, 2012
	>A> 5688801	Nov 18, 2014	U-543		I-596	May 15, 2012
	>A> 7547452	Nov 19, 2013	DP			
	>A> 7547452*PED	May 19, 2014				
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
021346 003	>A> 5688801	Nov 18, 2014	U-972		I-597	May 15, 2012
	>A> 5688801	Nov 18, 2014	U-543		I-596	May 15, 2012
	>A> 7547452	Nov 19, 2013	DP			
	>A> 7547452*PED	May 19, 2014				
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
021346 004	>A> 5688801	Nov 18, 2014	U-972		I-597	May 15, 2012
	>A> 5688801	Nov 18, 2014	U-543		I-596	May 15, 2012
	>A> 7547452	Nov 19, 2013	DP			
	>A> 7547452*PED	May 19, 2014				
<u>RISPERIDONE - RISPERIDONE</u>						
076440 001					PC	Jul 29, 2009
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
022008 006	5422123	Jun 06, 2012	DP		NDF	Jun 13, 2011
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
021366 002	>A> 6316460	Aug 04, 2020	DP		>A> I-573	Nov 06, 2011
	>A> 6316460*PED	Feb 04, 2021			>A> I-547	Nov 08, 2010
	>A> 6858618	Dec 17, 2021	U-618		>A> PED	May 06, 2012
	>A> 6858618*PED	Jun 17, 2022			>A> PED	May 08, 2011
	>A> RE37314	Jan 08, 2016	DS			
	>A> RE37314*PED	Jul 08, 2016				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
021366 003	>A> 6316460	Aug 04, 2020	DP		>A> I-573	Nov 06, 2011
	>A> 6316460*PED	Feb 04, 2021			>A> I-547	Nov 08, 2010
	>A> 6858618	Dec 17, 2021	U-618		>A> PED	May 06, 2012
	>A> 6858618*PED	Jun 17, 2022			>A> PED	May 08, 2011
	>A> RE37314	Jan 08, 2016	DS			
	>A> RE37314*PED	Jul 08, 2016				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
021366 004	>A> 6316460	Aug 04, 2020	DP		>A> I-573	Nov 06, 2011
	>A> 6316460*PED	Feb 04, 2021			>A> I-547	Nov 08, 2010
	>A> 6858618	Dec 17, 2021	U-618		>A> PED	May 06, 2012
	>A> 6858618*PED	Jun 17, 2022			>A> PED	May 08, 2011
	>A> RE37314	Jan 08, 2016	DS			
	>A> RE37314*PED	Jul 08, 2016				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
021366 005	>A> 6316460	Aug 04, 2020	DP		>A> I-573	Nov 06, 2011
	>A> 6316460*PED	Feb 04, 2021			>A> I-547	Nov 08, 2010
	>A> 6858618	Dec 17, 2021	U-618		>A> PED	May 06, 2012
	>A> 6858618*PED	Jun 17, 2022			>A> PED	May 08, 2011
	>A> RE37314	Jan 08, 2016	DS			
	>A> RE37314*PED	Jul 08, 2016				
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
020692 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
<u>SILDENAFIL CITRATE - REVATIO</u>						
021845 001					I-598	May 07, 2009
<u>SILODOSIN - RAPAFLO</u>						
022206 001	5780485	Nov 13, 2012	U-902			
<u>SILODOSIN - RAPAFLO</u>						
022206 002	5780485	Nov 13, 2012	U-902			
<u>SINECATECHINS - VEREGEN</u>						
021902 001	5795911	Oct 31, 2020	U-172			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 001					I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 004	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 005	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 006	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - HUMATROPE</u>						
019640 007	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 004	5849700	Dec 15, 2015		U-340		
	5849704	Dec 15, 2015	DP	U-340		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 005	5849700	Dec 15, 2015		U-340		
	5849704	Dec 15, 2015	DP	U-340		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 006	5849700	Dec 15, 2015		U-340		
	5849704	Dec 15, 2015	DP	U-340		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
021148 007	5849700	Dec 15, 2015		U-340	I-572	Oct 31, 2011
	5849704	Dec 15, 2015	DP	U-340	I-551	Sep 20, 2010
					I-536	May 31, 2010
					ODE	May 31, 2014
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076572 001					PC	Aug 08, 2009
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076840 001					PC	Aug 08, 2009
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076840 002					PC	Aug 08, 2009
<u>SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE</u>						
076840 003					PC	Aug 08, 2009
<u>SUNITINIB MALATE - SUTENT</u>						
021938 004	6573293	Feb 15, 2021	DS DP	U-703	NCE	Jan 26, 2011
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020		U-883		
<u>TADALAFIL - ADCIRCA</u>						
022332 001	>A> 5859006	Nov 21, 2017	DS DP	U-975	NP	May 22, 2012
	>A> 6821975	Nov 19, 2020	DS DP		>A> ODE	May 22, 2016
	>A> 7182958	Apr 26, 2020	DP			
<u>TELBIVUDINE - TYZEKA</u>						
022154 001					NCE	Oct 25, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEMOZOLOMIDE - TEMODAR</u>						
022277 001	5260291	Aug 11, 2013	DS DP U-619			
	5260291*PED	Feb 11, 2014				
	6987108	Sep 08, 2023	DP			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
021318 001	>A> 7550434	Dec 08, 2018	DP U-982			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
021318 002	>A> 6770623	Dec 08, 2018	DP U-982			
	>A> 6977077	Aug 19, 2019	U-982			
	>A> 7144861	Dec 08, 2018	DP			
	>A> 7163684	Aug 19, 2019	U-983			
	>A> 7351414	Aug 19, 2019	U-984			
	>A> 7550434	Dec 08, 2018	DP U-982			
<u>TIGECYCLINE - TYGACIL</u>						
021821 001					I-588	Mar 20, 2012
					I-587	Mar 20, 2012
					I-586	Mar 20, 2012
<u>TOLVAPTAN - SAMSCA</u>						
022275 001	>A> 5258510	Nov 02, 2010	DS		NCE	May 19, 2014
	>A> 5753677	May 19, 2015	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
022275 002	>A> 5258510	Nov 02, 2010	DS		NCE	May 19, 2014
	>A> 5753677	May 19, 2015	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
022275 003	>A> 5258510	Nov 02, 2010	DS		NCE	May 19, 2014
	>A> 5753677	May 19, 2015	U-978			
<u>TOPIRAMATE - TOPAMAX</u>						
020505 001	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 002	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 003	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 004	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 005	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020505 006	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPAMAX</u>						
020844 001	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX</u>						
020844 002	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
020844 003	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
<u>TOPIRAMATE - TOPIRAMATE</u>						
076448 001					PC	Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
076448 002					PC	Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
077868 001					PC	Oct 12, 2009
<u>TOPIRAMATE - TOPIRAMATE</u>						
077868 002					PC	Oct 12, 2009
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 001					NP	Dec 30, 2011
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 002					NP	Dec 30, 2011
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
021745 003					NP	Dec 30, 2011
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
022278 001					NCE ODE	Dec 16, 2009 Dec 16, 2011
<u>ZOLEDRONIC ACID - RECLAST</u>						
021817 001					I-595 I-584 I-581	May 29, 2012 Mar 15, 2012 Dec 19, 2011
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
021997 001	6761910	Sep 24, 2018	DP U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
021997 002	6761910	Sep 24, 2018	DP U-674			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 29th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>